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Abstract
Polyunsaturated fatty acids (PUFA) have therapeutic effects in inflammatory diseases, 
however the specific mechanisms by which they exert these effects have not yet been 
defined. Several studies have shown involvement of toll like receptor TLR2 and 
TLR4 in some of these inflammatory diseases shown to be inhibited by PUFA. In 
order to determine how PUFA exert their beneficial effects in these diseases it is 
important to examine how PUFA modulate the expression and activation of TLR2 and 
TLR4 and their downstream signalling pathways. This study investigates the effects 
of a number of PUFA, including conjugated linoleic acid (CLA), docosahexaenoic 
acid (DHA) and eicosapentaenoic acid (EPA), on MAP kinase signaling pathways and 
cytokine production in macrophages following activation of these cells through these 
TLRs. Macrophages are key cells involved in activation of innate immune responses. 
This study used the J774 murine macrophage cell line as a model. The results 
demonstrate that PUFA exert distinct effects on both pro-inflammatory and anti­
inflammatory cytokine production depending on whether the cell is activated via 
TLR2 or TLR4. Thus, providing evidence that the effects of PUFA on immune cell 
function are highly dependent on the mode of activation of the cell. Furthermore, 
individual PUFA exert these effects through differential regulation of MAP kinase 
signalling proteins. Activation of ERK was found to be critical for mediating the 
effects of PUFA on cytokine production, with p38 being involved to a lesser extent. 
Given that these fatty acids can change the way in which an immune cell responds to 
activation through TLRs, further research must be undertaken in order to fully
elucidate the benefits of dietary supplementation with fatty acids and indeed to 
determine any drawbacks associated with their use.
Objectives
Dietary PUFA interact with multiple components of the immune system and modulate 
the balance of pro- and anti-inflammatory cells. TLR 2 and TLR 4 activate a common 
signalling pathway that results in the induction of inflammatory cytokines. We 
hypothesised that dietary PUFA could alter the response of immune cells following 
activation through TLRs and that this was mediated by MAPK activation. The main 
aim of this study was to examine the effects of various n-3 and n-6  PUFA on murine 
macrophage activation and function, which were determined by measuring cytokine 
secretion, cell surface marker expression and intracellular signalling. We measured 
these responses following activation of the macrophages through TLR4 and TLR2.
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Chapter 1 
General Introduction
1.0 General Introduction
1.1 Immunity:
Immunity refers to the state of protection from infectious disease; there are two types; 
innate immunity and adaptive immunity. Innate immunity is comprised of a set of 
disease resistant mechanisms, which are unspecific for particular pathogens (Janeway, 
2005). Phagocytic cells like macrophages play an important role in many aspects of 
innate and adaptive immunity and link these two differing responses (Janeway, 2005). 
Adaptive immunity however displays high specificity in relation to pathogen and has 
a remarkable property in immunological memory (Janeway, 2005).
1.2 Innate Immune System:
The innate immune system is widely believed to constitute an evolutionary defence 
strategy and one which is the dominant immune system found in fungi, plants, insects 
and in multicellular organisms (Janeway, 2005). The main functions of the vertebrate 
innate immune system are recruitment of immune cells to sites of infection and 
inflammation; activation of the complement cascade to identify bacteria; activate cells 
and clearance of dead cells and antibody complexes; the identification and removal of 
foreign molecules present in organs, tissues, blood and lymph fluids by utilising 
specialised white blood cells and the activation of the adaptive immune system 
through antigen presentation (Lewis CE, 1999). The strategy of innate immune 
recognition is based on the detection of constitutive and conserved products of 
microbial metabolism. Many metabolic pathways and individual gene products are 
unique to micro-organisms and absent from host cells (Lewis CE, 1999). Some of 
these pathways are involved in housekeeping functions and their products are
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conserved among micro-organisms of a given class and are essential for their survival. 
For example, lipopolysaccharide (LPS), lipoproteins, peptidoglycan and lipoteichoic 
acids (LTAs) are all molecules made by bacteria, but not by eukaryotic cells (Lewis 
CE, 1999). Therefore, these products can be viewed as molecular signatures of 
microbial invaders, and their recognition by the innate immune system can signal the 
presence of infection. One important aspect of innate recognition is that its targets are 
not absolutely identical between different species of microbes (Janeway, 2005). 
However, although there are several strain- and species-specific variations of the fine 
chemical structure, these are always found in the context of a common molecular 
pattern, which is highly conserved and invariant among microbes of a given class. For 
example, the lipid-A portion of LPS represents the invariant pattern found in all 
Gram-negative bacteria and is responsible for the pro-inflammatory effects of LPS, 
whereas the O-antigen portion is variable in LPS from different species of bacteria 
and is not recognized by the innate immune system (Lewis CE, 1999).
Because the targets of innate immune recognition are conserved molecular patterns, 
they are called pathogen-associated molecular patterns (PAMPs). Accordingly, the 
receptors of the innate immune system that recognize PAMPs are called pattern- 
recognition receptors (PRR) (Janeway, 2005). PAMPs have three common features 
that make them ideal targets for innate immune recognition. First, PAMPs are 
produced only by microbes, and not by host cells. Therefore, recognition of PAMPs 
by the innate immune system allows the distinction between ‘se lf and ‘microbial 
non-self ’. Second, PAMPs are invariant between microorganisms of a given class. 
This allows a limited number of germ-line-encoded PRRs to detect the presence of 
any microbial infection. So, recognition of the conserved lipid-A pattern in LPS, for
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example, allows a single PRR to detect the presence of almost any Gram-negative 
bacterial infection. Third, PAMPs are essential for microbial survival. Mutations or 
loss of PAMPs are either lethal for that class of microorganisms, or they greatly 
reduce their adaptive fitness. Therefore, ‘escape mutants’ are not generated. These 
properties of PAMPs indicate that their recognition must have emerged very early in 
the evolution of host-defense systems. (Janeway, 2005)
Indeed, many PAMPs are recognized by the innate immune systems not only of 
mammals, but also of invertebrates and plants. PAMPs are actually not unique to 
pathogens and are produced by both pathogenic and non-pathogenic microorganisms. 
In fact, none of the gene products that are unique to pathogens —  the so-called 
‘virulence factors’ —  are known to be recognized by the mammalian innate immune 
system (Medzhitov, 2001). This means that PRRs cannot distinguish between 
pathogenic and commensal microorganisms. This distinction, however, is vitally 
important. We live in constant contact with commensal microflora, and continuous 
activation of inflammatory responses by commensals would have potentially lethal 
consequences for the host. This, however, does not occur under normal physiological 
conditions. The exact mechanisms that allow the host to ‘tolerate’ non-pathogenic 
microorganisms are largely unknown. Presumably, compartmentalization (for 
example, confinement of microflora to the luminal side of intestinal epithelium), as 
well as anti-inflammatory cytokines, such as transforming growth factor-[3 (TGF-(3) 
and interleukin (IL)-IO, have an important role in this process (Medzhitov, 2001).
The innate immune system uses various PRRs that are expressed on the cell surface, 
in intracellular compartments, or secreted into the blood stream and tissue fluids. The
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principal functions of PRRs include: opsonization, activation of complement and 
coagulation cascades, phagocytosis, activation of pro-inflammatory signaling 
pathways and induction of apoptosis.
1.3 Barriers To Infection:
There are three barriers to infection. These are mechanical, chemical and biological. 
The first mechanical meaning the physical barrier refers to the epithelial surfaces that 
form a physical barrier that is very impermeable to most infectious agents. Therefore 
the skin acts as our first line of defence against invading organisms (Janeway, 2005). 
Desquamation of skin epithelium helps in the removal of infectious agents that have 
adhered to the epithelial surfaces. Cilia movement helps in keeping air passages and 
the GI tract free from micro-organisms etc. Chemical barriers also protect against 
infection. The skin and respiratory tract secrete anti-microbial peptides such as p- 
defensins. Lysozyme and phopholipase A in saliva, tears are also antibacterial. Gastric 
acid and proteases in the stomach serve as powerful chemical defenses against 
ingested pathogens. Biological barriers such as the commensal flora in the GI tract 
compete with pathogenic bacteria for food space and can change conditions in the 
environment such as pH or available iron. This prohibits pathogens to reach sufficient 
numbers to cause illness. (Janeway, 2005)
Humoral Barriers:
There are also humoral barriers that include inflammation, the complement system 
and cellular barriers of the innate immune system. Humoral immunity refers to 
antibody production and the processes that follow including: Th2 activation, cytokine 
production, germinal centre formation, affinity maturation and memory cell
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generation. Humoral immunity also refers to the effector functions of antibodies, 
which include pathogen and toxin neutralisation, complement activation, opsonin 
promotion of phagocytosis and pathogen elimination (Janeway, 2005). The 
complement system is composed of approximately 2 0  different protein which work 
together to destroy pathogens and signal other immune cells to the threat. Activation 
of the complement system results in the production of split products which serve as 
mediators of inflammation. These mediators act together to induce monocytes and 
neutrophils to adhere to vascular endothelial cells, extravate and migrate toward the 
site of complement activation in the tissues (Janeway, 2005). Coagulation is another 
barrier this prevents bleeding and limits the spread of invading pathogens into the 
blood-stream.
Cellular Barriers:
Innate Cells:
Innate cells comprise a range of cells, including macrophage, dendritic cells, 
monocytes, neutrophils and natural killer cells. Dendritic cells (DCs) are potent 
antigen presenting cells (APCs) that possess the ability to stimulate naïve T cells. 
They comprise a system of leukocytes widely distributed in all tissues. DCs are 
derived from bone marrow progenitors and circulate in the blood as immature 
precursors prior to migration into peripheral tissues. Within different tissues, DCs 
differentiate and become active in the taking up and processing of antigens, and their 
subsequent presentation on the cell surface linked to major histocompatibility (MHC) 
molecules. Upon appropriate stimulation, DCs undergo further maturation and 
migrate to secondary lymphoid tissues where they present antigen to T cells and
induce an immune response (Janeway, 2005). Natural killer (NK) cells are a form of 
cytotoxic lymphocyte which constitute a major component of the innate immune 
system. NK cells play a major role in the host-rejection of both tumors and virally 
infected cells. They were named "natural killer" because of the initial concept that 
they do not require activation in order to kill cells which are "missing self” 
recognition.
Another innate immune cell, the neutrophil, is also known as a polymorphonuclear 
cell (PMNs) due to the polymorphic shape of its nucleus. The neutrophils main role is 
in inflammation. In the tissues, neutrophils are active phagocytic cells, like 
macrophages however, they do not act as antigen presenting cells. Neutrophils are the 
most abundant type of phagocytes and are the first to site of infection by a process 
called extravasation. They are attracted into the tissue by chemotactic factors, which 
include complement proteins, clotting proteins and T cell derived cytokines (see table 
4.1). Neutrophils, although not an antigen presenting cell (APC), are most effective at 
killing ingested micro-organisms and can do this by oxygen dependent or independent 
pathways (Janeway, 2003). Neutrophils react to pathogen by activating a respiratory 
burst containing oxidising agents such as hydrogen peroxide and hypochlorite.
Macrophage, greek for big eaters are cells within tissues that originate from specific 
white blood cells called monocytes. The monocytes and macrophages act in both 
innate and adaptive immunity (Lewis CE, 1999). Their role is to phagocytose (i.e. 
engulf and digest) cellular debris and pathogens and to stimulate lymphocytes and 
other immune cells to respond to pathogen. The macrophage is the major 
differentiated cell of the mononuclear phagocyte system. This system comprises bone 
marrow monoblasts and pro-monocytes, tissue macrophage and peripheral blood
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monocytes. Macrophage are found in the lymphoid organs, liver, lungs, GI tract, the 
central nervous system, bone, endothelial cells, fibroblasts, and monocytes. When 
monocytes enter the tissues and become macrophages they undergo several changes. 
The cells enlarge and increase the amount of intracellular lysosyme allowing 
enhanced phagocytosis. In the tissues, macrophages live for months or years and may 
be motile. Macrophages movement is enhanced using pseudopods, which also act to 
engulf pathogens and subsequent activation (Lewis CE, 1999).
Activated macrophages have an important role in phagocytosis, they recognize and 
remove unwanted particulate matter including products of inflammation and invading 
organisms, antigens and toxins (Lewis CE, 1999). Macrophages also have an 
important role in the presentation of antigens (as APC's) to T-helper cells and in 
activating T cells with IL-1 release. Receptors present on the surface of macrophages 
determine the control of activities, such as growth, differentiation, activation, 
recognition, endocytosis, migration and secretion. Numerous ligands have been 
reported as binding to the surface of macrophage (Table 1.0). The first of the 
macrophage receptors to be identified was those for the Fc region of the IgG molecule 
and for the cleavage product of the third component of the complement system (C3) 
(Lewis CE, 1999). The attachment of the Fc portions of Ig molecules to the surface of 
the macrophage via Fc receptors may trigger various functions such as endocytosis, 
the generation of transmembrane signals, resulting in the reorganisation of 
cytoskeletal microfilaments at the site of attachment facilitating phagocytosis and the 
secretion of potent mediators.
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Macrophages not only produce many cytokines they also possess receptors for such 
cytokines. Individual cytokines or combinations of cytokines interacting with specific 
receptors modulate the function of macrophages.
Table 1.0: Surface Receptors of monocytes and macrophages
Receptor Ligand
Fc Receptor 
Complement Receptors
IgG2a, IgG2b, /IgGi,IgG3iIgA, IgE 
C3b, C3bi, C5a, Clq
Cytokine Receptors MIF, MAF, LIF, CF, MFF, IL-1, IL-2, IL-3, IL-4, 
IFN-a, IFN-ß, IFN-y. Colony-stimulating factors 
(GM-CSF, M-CSF/CSF-1)
Receptors For Peptides and 
small molecules
Hi, H2, 5HT, 1,2,5-Dihydroxy Vitamin D3, N - 
formulated peptides, enkephalins/endorphins, 
substance P, arg-vasopressin.
Hormone Receptors Insulin, glucocorticosteroids, angiotensin.
Lipoprotein lipid receptors Anionic low-density lipoproteins, PGE2, LTB4 LTC4 
LTD4i PAG, apolipoproteins B and E (Chylomicron 
remnants, VLDL).
Receptors for coagulants and 
anticoagulants
Fibrinogen/Fibrin, coagulation factor VII, a l -  
antithrombin, heparin.
Others Cholinergic agonists, al-adrenergic agonists, ß2- 
adrenergic agonists.
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1.4 Activation, Antigen Processing And Presentation:
Mononuclear phagocytes and neutrophils provide a first line defense against microbial 
invasion. While the neutrophil is a more efficient phagocyte when the particle load is 
great or much larger than in relation to the cell macrophages become more effective. 
Macrophages move towards microbial particles guided by a gradient of chemotactic 
factors. Engulfment of microbial particle occurs through use of pseudopods and the 
recognition of PAMP’s by PRR’s by the macrophage (Lewis CE, 1999). The main 
PRR’s found on macrophage are the toll-like receptors (TLRs) and receptors for the 
Fc portion of antibodies. Upon engulfment the microbial particle is taken within a 
membrane-bound structure called a phagosome. The phagosome then enters the 
endocytic processing pathway eventually fusing with a lysosome. Lysosomes contain 
lysozyme and hydrolytic enzymes which digest the microbial particle. These digested 
particles can then either interact with MHC II molecules and finally presented to Th 
Cells or be released for further opsonisation (Lewis CE, 1999).
There are two types of activation for macrophages, classically activated and 
alternatively activated macrophages. Macrophages become classically activated by 
exposure to two signals, the first is the cytokine IFN-y which primes the macrophage 
but does not activate (Lewis CE, 1999). The second signal is tumor necrosis factor 
(TNF) or an inducer of TNF. The physiologically relevant second signal is usually 
the result of TLR ligation inducing production of endogenous TNF within the 
macrophage upon contact with a stimulus e.g. LPS (Luster et al., 2005a). Upon 
activation significant changes in cellular morphology and secretory profile of the cell 
occurs. A variety of chemokines including, IL-8 /CXCL8 , IP-10/CXCL10, MIP- 
la/CCL3, MIP-16/CCL4, and RANTES/CCL5, are secreted and act as
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chemoattractants for immature DC’s, neutrophils, natural killer cells and activated T 
cells. Several pro-inflammatory cytokines are also released including IL-1/3, IL-6 , 
and TNF-a (Duffield, 2003, Gordon, 2003, Ma et al., 2003, Mosser, 2003). TNF-a 
also contributes to the pro-apoptotic activity of classically activated macrophage. The 
release of these molecules is important in host defence and in direction of adaptive 
immune system, but unchecked massive infiltration of leukocytes and flooding of 
tissue with inflammatory mediators and pro-apoptotic factors can inflict serious tissue 
injury (Lewis CE, 1999).
Tissue destruction by chronic inflammation has also been associated with tumour 
development and type 1 autoimmune diseases. Alternatively activated macrophages 
do not require priming, IL-42 or IL-13 can act as efficient stimuli (Doherty et al., 
1993). The binding of these to the respective antigens is followed by pinocytosis of 
soluble antigen which is then loaded onto MHC class II molecules and displayed to 
Tcells (Conner and Schmid, 2003). The alternatively activated macrophage also 
changes its cellular morphology and secretory profile upon activation. Leukocytes are 
attracted by the macrophage through its release of chemokines which include 
MDC/CCL22, 30,31 PARC/CCL18, 32,33 and TARC/CCL17 (Imai et al., 1999). 
Inflammation is negated by the release of factors such as IL-lra, IL-10 and TGF-(5 
(Mosser, 2003). The alternatively activated macrophage also secretes PDGF, IGF that 
promote cell proliferation. These secreted molecules work to resolved inflammation 
and promote wound repair due to the anti-inflammatory, fibrotic and proliferative 
activites. Alongside its beneficial effects, the alternatively activated macrophage has 
been involved in allergy and asthma (Duffield, 2003, Gordon, 2003).
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The link between innate and adaptive immunity is “managed” by CD4+ lymphocytes 
or Th Cells. These CD4+ cells express T-Cell receptors (TCR’s) that recognise 
antigen bound to the MHC II molecules. Activation of these naive T helper cells 
causes release of cytokines which influence the activity of not only the antigen 
presenting cells that activated the T helper cells but many other cell types. Several 
types of effector CD4+ T helper cell responses can be induced by a professional APC 
(i.e. macrophage, dendritic cells, NK cells), these have been given the designation 
Thl and Th2. Both of these eliminate different types of pathogens. The Thl response 
is characterised by the production of IFN-y which activates the bactericidal activities 
of macrophages and induces B cells to make opsonizing antibodies leading to cell- 
mediated immunity (Luster et al., 2005a). The Th2 response is characterised by the 
release of IL-4 which results in the activation of B cells to make neutralizing 
antibodies leading to humoral immunity (Luster et al., 2005a).
A distinct subset of the T helper cells, T hl7 has been identified. Thl7 cells produce 
IL-J7, TNF-a and IL-6 . EL-17 is a potent inflammatory cytokine and is involved in 
inducing expression of proinflammatory cytokines, IL-6  and TNF, and chemokines 
(such as KC, MCP-1 and MIP-2) (Bettelli et al., 2007). This subset is regulated by 
TGF-P, IL-6  and IL-23 and inhibited by IL-4 and IFN-y the cytokine involved in 
macrophage priming. IL-17 stimulates fibroblasts, endothelial cells and macrophages 
to produce pro-inflammatory mediators IL-1, IL-6 , TNF-a and chemokines. IL-17 
also activates enhanced granulocytes, macrophages, NK cells and CD8 Tcells.
Regulatory Tcells or Treg are a specialised subpopulation of T cells that suppress 
activation of the immune system maintaining homeostasis and tolerance to self
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antigens (Roncarolo and Levings, 2000). These Treg cells are also only activated 
when bound to its antigen on the MHC class II molecule of an APC for which it is 
specific. Besides naturally occurring CD4+ CD25+ Treg cells, other CD4+ Treg cells 
include Tr-1 cells secreting interferon (IFN)-y and IL-10, and Th3 cells secreting high 
levels of transforming growth factor (TGF)-P, IL-4, and IL-10 (Roncarolo and 
Levings, 2000).
1.5 Adaptive Immunity
The adaptive immune system is composed of highly specialised systemic cells and 
processes, which eliminate pathogenic challenges. The adaptive immune system is 
activated by the innate immune system which is the first line of defence against 
invading pathogens (Janeway, 2005). The major functions of the adaptive immune 
system include recognition of specific “non-self’ antigens in the presence of “se lf’ 
antigens during antigen presentation. The main cells of the adaptive immune system 
are the B and T lymphocytes. T lymphocytes are a major source of cytokines 
(Janeway, 2005). There are two main subsets of T lymphocytes, distinguished by the 
presence of cell surface molecules known as CD4 and CD8 . T lymphocytes 
expressing CD4 are also known as helper T cells. This subset can be further 
subdivided into Thl and Th2, and the cytokines they produce are known as Thl-type 
cytokines and Th2-type cytokines. Thl cells produce IFN-y, 1L-2, TNF-a. and 
lymphotoxin. IFN-y is the main Thl cytokine (Janeway, 2005). The Th2-type 
cytokines include IL 4, IL 5 and IL 13, which are associated with the promotion of 
IgE and interleukin-10, which has more of an anti-inflammatory response. In excess, 
Th2 responses will counteract the Thl mediated microbicidal action.
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As discussed earlier macrophage are an important antigen presenting cell and require 
two signals for activation. One is IFN-y and the other can come from varied means 
e.g. LPS but is required to sensitise the macrophage to respond to IFN-y. Effector 
Th1 cells can deliver both signals. IFN-y is a characteristic cytokine produced by 
armed TH1 cells whereas the CD40 ligand expressed by TrI cells provides the 
sensitisation through contact with CD40 on macrophage (Janeway, 2005). This 
causes TH1 cells to secrete IFN-y, this subsequently binds to the IFN-y receptors on 
macrophage causing activation. This activation causes the secretion of TNF-a, IL-1, 
and IL-12. TNF-a and IL-1 promote inflammation to recruit phagocytic leukocytes 
while 1L-12 enables naive Tcells to differentiate into Thl cells (Janeway, 2005).
1.6 Cytokines
Cytokines are small, secreted proteins which mediate and regulate immunity, 
inflammation, and haematopoiesis (Janeway, 2005). They must be produced de novo 
in response to an immune stimulus. They generally act over short distances and short 
time spans and at very low concentration. They act by binding to specific membrane 
receptors, which then signal the cell via second messengers, often tyrosine kinases, to 
alter gene expression (Medzhitov, 2001). Responses to cytokines include increasing 
or decreasing expression of membrane proteins (including cytokine receptors), 
proliferation, and secretion of effector molecules. Cytokine is a general name; other 
names include lymphokine, monokine, chemokine, and interleukin. Cytokines act in 
an autocrine, paracrine and endocrine manner. It is common for different cell types to 
secrete the same cytokine or for a single cytokine to act on several different cell types. 
Cytokines are made by many cell populations, but the predominant producers are
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helper T cells (Th) and macrophages (Lewis CE, 1999). The largest group of 
cytokines stimulates immune cell proliferation and differentiation. This group 
includes interleukin 1 (IL-1), which activates T cells; IL-2, which stimulates 
proliferation of antigen-activated T and B cells; IL-4, IL-5, and 1L-6, which stimulate 
proliferation and differentiation of B cells; Interferon gamma (IFN-y), which 
activates macrophages; and 1L-3, IL-7 and granulocyte monocyte colony-stimulating 
factor (GM-CSF), which stimulate haematopoiesis (Janeway, 2005). Cytokines are 
also grouped into pro-inflammatory and anti-inflammatory cytokines. Anti­
inflammatory cytokines include: IL-4, IL-6 , IL-10 and TGF-ll (Lalani et al., 1997). 
Pro-inflammatory cytokines include: IL-ip, IL-12, and TNF-a. See table 1.1 for list 
of cytokines and their biological function.
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Table 1.1 Cytokines: sources and functions
Name Source Function I
IL-I Macrophages
Small amounts induce acute phase reaction, large 
amounts induce fever.
IL-2 [THl-cells
Stimulates growth and differentiation of T cell 
response. Can be used in immunotherapy to treat 
cancer or suppressed for transplant patients.
IL-4
TH2-cells, just activated 
naive CD4+ cell, memory 
CD4+ cells
Involved in proliferation of B cells and the 
development of T cells and mast cells. Important 
role in allergic response (IgE).
1L-6 Macrophages, TH2-cells Induces acute phase reaction
IL-10
Monocytes, TH2-cells, 
mast cells
Inhibits Thl cytokine production
IL-12 Macrophages NK cell stimulation, Thl cells induction. May suppress food allergies.
IL-13 TH2-cells
Stimulates growth and differentiation of B-Cells 
(IgE), inhibits THl-cells and the production of 
macrophage inflammatory cytokines
IL-17 T cells
Induces production of inflammatory cytokines, 
and maintains inflammation
IL-18 Macrophages Induces production of Interferon-gamma (IFNy)
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Interleukin 10:
IL-10 is one of the most important anti-inflammatory cytokines found within the 
human immune response. It is a potent inhibitor of Thl cytokines, including both IL-2 
and IFN-y. This activity accounts for its initial designation as cytokine synthesis 
inhibition factor (Howard and O'Garra, 1992, Lalani et al., 1997, Opal et al., 1998). 
In addition to its activity as a Th2 lymphocyte cytokine, IL-10 is also a potent 
deactivator of monocyte/macrophage pro-inflammatory cytokine synthesis 
(Brandtzaeg et al., 1996, Clarke et al., 1998). IL-10 is primarily synthesized by CD4+ 
Th2 cells, monocytes, and B cells and circulates as a homodimer consisting of two 
tightly packed 160-amino-acid proteins (Howard and O'Garra, 1992). After engaging 
its high-affinity 110-kd cellular receptor, IL-10 inhibits monocyte/macrophage- 
derived TNF-a, IL-1, IL-6 , IL-8 , IL-12, granulocyte colony-stimulating factor, MIP- 
la , and MIP-2a (Brandtzaeg et al., 1996, Gerard et al., 1993, Marchant et al., 1994b). 
IL-10 inhibits cell surface expression of major histocompatibility complex class II 
molecules, B7 accessory molecules, and the LPS recognition and signaling molecule 
CD14 (Opal et al., 1998). It also inhibits cytokine production by neutrophils and 
natural killer cells. IL-10 inhibits nuclear factor kB (NF-kB) nuclear translocation 
after LPS stimulation and promotes degradation of messenger RNA for the pro- 
inflammatory cytokines (Clarke et al., 1998).
In addition to these activities, IL-10 attenuates surface expression of TNF receptors 
and promotes the shedding of TNF receptors into the systemic circulation 
(Dickensheets et al., 1997, Joyce et al., 1994). IL-10 is readily measurable in the 
circulation in patients with systemic illnesses and a variety of inflammatory states 
(Marchant et al., 1994a, van der Poll et al., 1997). IL-10 is present in sufficient
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concentrations to have a physiologic impact on host responses to systemic 
inflammation. In the case of inflammatory bowel disease (IBD) especially colitis, loss 
of tolerance against bacterial flora of intestine is the causative agent (Braat et al., 
2003). Tolerance against flora requires recognition of antigens by PRRs and presence 
of regulatory cells and cytokines.
Peptidoglycan activates TLR2. Stimulation of TLR2 triggers association with an 
adapter protein, myeloid differentiation primary response protein 88  (MyD8 8 ), 
and the recruitment of interleukinl- receptor-associated kinase (IRAK) proteins. 
TNF- receptor-associated factor 6  (TRAF6 ) initially binds to this complex and then 
dissociates to interact with transforming growth factor-p-activated kinase- 1
(TAK1), which in association with other proteins leads to the activation and 
phosphorylation of components of the IKK (inhibitor of NFkB kinase) complex that 
gives rise to downstream activation of NFkB (p50 and p65 subunits) leading to 
activation of the inflammatory cytokine cascade (Rakoff-Nahoum et al., 2004). The 
cytokines and factors produced as a result of activation of pattern-recognition 
receptors can help initiate or sustain host responses that are anti-inflammatory (eg, 
interleukin 10 and transforming growth factor P) or pro-inflammatory (eg, TNFa and 
interleukin 1 2 ).
IL-10 plays a critical role in the shaping of immune responses. Produced by activated 
macrophages and Th2 T cells, IL-10 promotes the development of humoral, Th2 
cytokine-driven immune responses (Moore et al., 1993). IL-10 inhibits the
development of Thl immune responses (Fiorentino et al., 1991), by reducing the 
capacity of macrophages to produce IL-12, a potent inducer of Thl immune responses 
(Bohn and Autenrieth, 1996). IL-10 has been proposed to exert a regulatory effect in
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intestinal mucosa (Niessner and Volk, 1995, Schreiber et al., 1995). The importance 
of IL-10 in shaping mucosal immune responses has been demonstrated by the 
spontaneous onset of inflammation in the IL-10-deficient mouse (Kuhn et al., 1993). 
IL-10-deficient mice spontaneously develop enterocolitis when housed in 
conventional environments, but when housed in SPF conditions IL-10-deficient mice 
develop inflammation limited to the colon, suggesting that resident enteric flora play a 
role in the development of spontaneous colitis in these mice.
IL-10 has an important role in regulatory network of cytokines controlling mucosal 
tolerance and is a potent anti-inflammatory therapy in IBD. In patients with ulcerative 
colitis, the pattern of cytokine expression shows increased expression of IL-5, IL-6 , 
IL-10, and IL-13 (Madsen, 2002). The therapeutic experience of IL-10 in animal 
models of colitis is very encouraging. In vitro studies have shown that exogenous IL- 
1 0  can down-regulate the enhanced pro-inflammatory cytokine release from lamina 
propria mononuclear cells isolated from patients with Crohn's disease (Steidler et al., 
2000). Direct administration of the anti-inflammatory cytokine EL10 into localised 
area has been studied with little therapeutic benefit due to its short half life ex-vivo 
(van Deventer et al., 1997). Genetically engineered bacteria such as Lactococcus 
lactis expressing IL-10 have also shown reduction in colitis in animal models and 
humans (Steidler et al., 2000). Schering- Plough has isolated the gene for IL-10 and 
is producing a recombinant form of the cytokine called tenovil. This has reached 
phase 3 trials.
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IL-12 is an interleukin, which is naturally produced by macrophages in response to 
antigenic stimulation. It is composed of a bundle of four alpha helices. It is a 
heterodimeric cytokine, which is encoded by two separate genes, IL-I2p35 and IL- 
12p40. The bioactive form of IL-12 is a 75 kDa heterodimer (IL12p70) comprised of 
independently regulated disulfide-linked 40 kDa (p40) and 35 kDa (p35) subunits. 
The p40 subunit exists extracellularly as a monomer (IL12p40) or dimer (IL12 (p40)2) 
and can antagonize the action of IL12p70 (Trinchieri, 1994). The highly coordinated 
expression of p40 and p35 genes to form IL-12 p70 in the same cell type at the same 
time is essential for the initiation of an effective immune response. It is known as a T 
cell stimulating factor, which can stimulate the growth and function of T cells. IL-12 
induces IFN-y synthesis and promotes Thl cell differentiation whereas the production 
of IL-10 by macrophages and a subset of B cells antagonizes the activities of IL-12 
(Trinchieri, 1994).
Pro-inflammatory cytokines such as IL-12 are strictly regulated. For example IFN-y, 
TNF-a and GM-CSF can induce cell production of IL-12. IL-10 as mentioned before 
is an effective inhibitor of IL-12. IL-12 also has immunoregulatory properties, and 
plays a vital role in development of immunity to intracellular pathogens. A number of 
these pathogens including Leishmania, measles virus and human immunodeficiency 
virus (HIV) have shown subversion of the development of cell-mediated immunity 
through inhibition of IL-12 production. The interaction of Leishmania spp, measles 
virus, and HTV with macrophages and monocytes results in a marked decrease in IL- 
12 production (Chougnet et al„ 1996). Ligation of phagocytic receptors on 
macrophage has also shown suppression of IL-12 production. This is achieved by two
IL-12
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distinct mechanisms, one depends on direct inhibition of gene transcription the second 
relies on inhibitory cytokine production. The production of IL-12 p40 is regulated 
primarily at the transcriptional level. The IL-12 p40 promoter contains multiple 
potential transcription-factor binding sites, three of which have been directly 
implicated in p40 gene regulation (Ma et al., 1997). The ligation of phagocytic 
receptors on human monocytes or murine macrophages has recently been shown to 
suppress IL-12 production. CR3 (CDllb/CD18, Mac-1) and the Fc receptors are the 
two phagocytic receptor classes that have been shown to have the clearest role in 
down-regulating IL-12 in these systems (Marth and Kelsall, 1997). The ligation of 
either CR3 or FcgR with monoclonal antibodies or with particulate ligands results in a 
profound inability of monocytes or macrophages to produce EL-12 in response to a 
variety of pro-inflammatory stimuli, including LPS, S. aureus, and CD40 ligand 
(Marth and Kelsall, 1997).
IL-12 has shown to be an important bridge between innate and adaptive immunity due 
to its activation of T cells to a ThI cell. Overproduction of the cytokine leads to 
inflammatory states and it has been shown to be involved in IBD and RA.
TNF-a:
TNFa is another cytokine involved in systemic inflammation and is also a member of 
a group of cytokines which stimulate the acute phase reaction. TNFa causes cell 
death, proliferation, differentiation, inflammation, viral replication etc. Its primary 
role however is in the regulation of immune cells. Dysregulation and overproduction 
of TNFa has been implicated in a variety of diseases as well as cancer. TNFa is
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mainly produced by macrophages although lymphoid cells, mast cells, endothelial 
cells, fibroblasts and neuronal tissue can also produce it. TNFa attracts neutrophils 
very potently and helps them to adhere to the endothelial cells for migration. It also 
stimulates phagocytosis and production of IL-1 oxidant and the inflammatory lipid 
prostaglandin E2 PGE2. An increasing concentration of TNFa will cause the cardinal 
signs of inflammation, heat, swelling, redness and pain. TNFa plays a central role in 
chronic inflammation (Podolsky, 2002). During activation of the inflammation 
cascade, antigen-presenting cells such as macrophages cause the activation and 
differentiation of CD4+ T lymphocytes. T lymphocyte cells differentiate into T helper 
(Th)-l and Th-2 cells. Th-1 cells secrete interferon gamma (IFN7) and interleukin 
(IL)-2, IL-12, and IL-18, whereas Th-2 cells secrete IL-4, IL-5, IL-6 , IL-10, and IL-13 
(Louis, 2001). Interferon gamma from the Th-1 response stimulates macrophages to 
produce TNFa.
TNFa is a pro-inflammatory mediator that has been shown to play an integral role in 
the pathogenesis of IBD. Transcription of the TNFa gene in activated macrophages 
results in the secretion of TNFa (Podolsky, 2002). Circulating soluble TNFa binds to 
two TNFa receptors mediating activation of other macrophages, augmentation of the 
T cell response, and recruitment of neutrophils to local sites of inflammation 
(Sandborn and Hanauer, 1999). TNFa also up-regulates other pro-inflammatory 
mediators such as IL-6  and IL-113 (Louis, 2001). High levels of pro-inflammatory 
cytokines, including TNFa, in the intestinal mucosa are pivotal in the development of 
relapses and for sustaining chronic inflammation (Mascheretti et al., 2004). There are 
several ways of inhibiting TNFa, including binding and neutralizing the molecule by 
monoclonal antibodies, blocking TNFa production and secretion either directly or
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indirectly, and inhibiting soluble TNFa receptors. Thalidomide inhibits TNFa 
production in monocytes, T lymphocytes, and macrophages. In a rat model of 
experimental colitis, thalidomide effectively decreased colitis, through the inhibition 
of TNFa in addition to its anti-angiogenic properties (Kenet et al., 2001).
1.7 Toll-Like Receptors:
Toll-like receptors are a conserved family of receptors involved in the recognition of a 
wide range of microbial molecules. TLRs comprise a family of type I transmembrane 
receptors, which are characterized by an extracellular leucine-rich repeat (LRR) 
domain and an intracellular Toll/IL-1 receptor (TIR) domain. The prototypic receptor 
Toll was first identified in the fruit fly Drosophila. Since then 10 TLR’s have been 
identified in humans and 13 in mice (Janeway, 2006). TLR’s are a type of PRR’s. 
Each of the TLR receptors recognizes a small range of conserved molecules from a 
group of pathogens. These molecules are called pathogen-associated molecular 
patterns (PAMPs). These PAMPs are common molecular motifs found on pathogens. 
Toll-like receptors recognize these specific patterns and regulate the activation of both 
innate and adaptive immunity (Hirschfeld et al., 2001).
Ligands for the TLR’s have been established although not fully and are shown in table 
1.2. After recognition of microbial pathogens TLRs trigger intracellular signaling 
pathways that result in the induction of inflammatory cytokines, IFN, and 
chemokines. TLRs also activate a common signaling pathway that results in the
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induction of inflammatory cytokines such as TNFa, IL-6 , IL-1(3, and IL-12. 
Macrophages phagocytose bacteria into a phagosome to be degraded. In the absence 
of TLRs or one of its adaptor molecules MyD8 8 , internalisation of bacteria was 
delayed and degradation of bacteria was less efficient (Watts, 2004). In macrophages 
and dendritic cells, the pathogen is exposed to the TLRs. In this way, the TLRs 
identify the nature of the pathogen and turn on an effector response appropriate for 
dealing with it. These signaling cascades lead to the expression of various cytokine 
genes.
Table 1.2 Toll-like Receptor Ligands
Receptor Ligand(s) Adaptor(s) Location
TLR1 Triacyl lipoproteins MyD8 8 /Mal Cell surface
TLR2 Lipoproteins, gram-positive 
peptidoglycan, lipoteichoic 
acids, fungi, viral glycoproteins
MyD8 8 /Mal Cell surface
TLR3 DS-RNA, poly I:C TRIF Cell
compartment
TLR4 LPS, viral glycoproteins, HSP60 MyD8 8 /MAL/TR
IF/TRAM
Cell surface
TLR5 Flagellin MyD88 Cell surface
TLR6 Diacyl lipoproteins MyD8 8 /Mal Cell surface
TLR7 Small synthetic compounds, ss- 
RNA
MyD88 Cell
compartment
TLR8 Small synthetic compounds, ss- 
RNA
MyD8 8 Cell
compartment
TLR9 Unmethylated CpG DNA MyD88 Cell
compartment
2 6
TLR 2:
TLR 2 is expressed on microglia, schwann cells, monocytes, macrophage, dendritic 
cells, polymorphonuclear leukocytes, B and T cells including Tregs. TLR2, in 
association with TLR1 or TLR6 , recognizes various bacterial components, including 
peptidoglycan, lipopeptide and lipoprotein of Gram-positive bacteria and mycoplasma 
lipopeptide. There are five subfamilies within the TLR family. The TLR2 subfamily is 
composed of TLR1, TLR2, TLR6 , and TLR 10 (Takeuchi et al., 1999). TLR2 
recognizes several atypical types of LPS from Leptospira interrogans and 
Porphyromonas gingivalis, in contrast to TLR4, which recognizes LPSs from 
enterobacteria such as Escherichia coli and Salmonella spp (Hirschfeld et al., 2001). 
The properties of the atypical LPSs recognized by TLR2 differ structurally and 
functionally from the enterobacteria LPS recognized by TLR4.
One aspect of TLR2 ligand recognition involves cooperation with other TLR family 
members, in particular TLR6  and TLR1, which confer discrimination among different 
microbial components. TLR2 and TLR6 co-immunoprecipitate, suggesting that they 
physically interact in the cell (Ozinsky et al., 2000). TLR1 has also been reported to 
associate with TLR2. TLR1/TLR2 heterodimers recognize a variety of bacterial 
lipopeptides, including the 19 kDa mycobacterial lipoprotein (Takeuchi et al., 2002), 
meningococcal lipoproteins (Wyllie et al., 2000), and the synthetic lipoprotein 
structure PAM3CSK4 (Takeuchi et al., 2001). TLR6/TLR2 heterodimers recognize 
mycoplasma lipoproteins (MALP) and, potentially, peptidoglycan (Imler and 
Hoffmann, 2001).
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CD 14, a co-receptor required for LPS recognition and down-stream effects mediated 
by TLR4 has also been shown to be required for signaling induced by TLR2 ligands. 
In the case of TLR2, the presence of CD14 enhances the efficiency of recognition by 
TLR2 to many ligands (Werts et al., 2001). There are a variety of cytokines produced 
by TLR2 signalling, including TNFa, IL-2, IL-6 , IL-12 and MIP-2. TLR2 mediated 
cellular activation may play a role in protection from pathogens that contain specific 
TLR2 ligands. For example, TLR2 knockout mice were shown to be more prone to 
morbidity and mortality due to pneumococcal meningitis. Higher expression of TLR2 
was also found in both Crohns disease and ulcerative colitis suggesting that an 
abnormal mechanism may provide an excess of inflammatory mediators during the 
active phases of IBD (Canto et al., 2006).
TLR 4:
TLR4 is expressed on monocytes, macrophage, dendritic cells, B cells, mast cells, 
epithelial cells and endothelial cells. TLR4 is the best studied of the family of 
receptors. It binds to LPS, as well as host protein molecules released at site of 
infection and damage, e.g. heat shock protein 60 (HSP60). HSPs such as HSP60 and 
HSP70 are normally intracellular proteins, but can also become "danger" molecules 
when released under stress or following excessive apoptosis. They activate 
macrophages via TLR-2 and TLR-4 to secrete pro-inflammatory cytokines such as 
TNF-a and IL-12, and to over-express co-stimulatory molecules on APCs (Smiley et 
al., 2 0 0 1 ).
The recognition of LPS requires other molecules in addition to TLR4. LPS binds to 
LPS-binding protein, and this LPS-LPS-binding protein complex is subsequently 
recognized by CD14, a glycosylphosphatidylinositol-anchored molecule preferentially
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expressed in macrophages and neutrophils. LPS stimulation is followed by increased 
physical proximity between CD14 and TLR4 (Da Shilva et al, 2001). MD-2 another 
required molecule associates with the extracellular portion of TLR4 and enhances 
LPS responsiveness (Akashi et al., 2000). In IBD patients levels of expression of 
TLR4 are higher than those in normal patients also suggesting like in TLR2 that an 
abnormal mechanism may provide an excess of inflammatory mediators during the 
active phases of IBD (Canto et al., 2006). Polymorphisms have also been studied in 
TLR4 with levels of polymorphs higher in ulcerative colitis and Crohns disease 
patients compared to control population (Canto et al., 2006). This could account for 
the persistence of the disease within families.
TLR Signaling
The activation of TLR signaling pathways originates from the cytoplasmic TIR 
domains. In the signaling pathway downstream of the TIR domain, a TIR domain- 
containing adaptor, MyD8 8 , was first characterized to play a crucial role. In addition, 
recent accumulating evidence indicates that TLR signaling pathways consist, at least, 
of a MyD8 8 -dependent pathway that is common to all TLRs, and a MyD8 8 - 
independent pathway that is peculiar to the TLR3- and TLR4 signaling 
pathways (Akira et al., 2001). (See fig 1.0 for signalling pathways).
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Fig 1.0 TLR pathways (taken from Arthritis Research and Therapy)
MyD88 Dependent Pathway
MyD88 possesses the TIR domain in the C-terminal portion, and a death domain in 
the N-terminal portion. MyD88  associates with the TIR domain of TLRs. Upon 
stimulation, MyD88  recruits IL-1 receptor-associated kinase (IRAK) to TLRs through 
interaction of the death domains of both molecules. IRAK is activated by 
phosphorylation and then associates with TRAF6 , leading to the activation of two 
distinct signaling pathways, and finally to the activation of JNK and NF-kB as shown 
in fig 1.0. MyD88  knockout mice showed no responses to the TLR4 ligand LPS in 
terms of macrophage production of inflammatory mediators, B cell proliferation, or 
endotoxin shock (Kawai et al., 1999). The cellular responses to the TLR2 ligands 
peptidoglycan and lipoproteins were abolished in MyD8 8  knockout mice (Takeuchi et 
al., 2000). An alternatively spliced variant of MyD8 8 , MyD8 8 s, which lacks the
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intermediate domain, has been shown to be induced by LPS stimulation and to inhibit 
LPS-induced NF-_B activation through inhibition of IRAK activity (Bums et al.,
2003, Janssens et al., 2002). Thus, MyD8 8 s may negatively regulate the 
inflammatory responses triggered by LPS.
MyD88 Independent Pathway
MyD88 knockout mice did not show any production of inflammatory cytokines, such 
as TNF-a and IL-12, in response to any of the TLR ligands. Studies demonstrated that 
there is a MyD8 8 -independent pathway as well as a MyD8 8 -dependent pathway in 
TLR signaling. In the MyD8 8 -independent pathway, LPS stimulation leads to 
activation of the transcription factor IRF-3, and thereby induces IFN-y. IFN-y, in turn, 
activates Statl, leading to the induction of several IFN-inducible genes (Doyle et al., 
2002, Hoshino et al., 2002, Toshchakov et al., 2002). In addition to the TLR4 ligand, 
the TLR3 ligand dsRNA has been shown to induce activation of NF-kB in MyD88 
knockout cells (Alexopoulou et al., 2001). IRF-3 also associates with IKK’s, which 
induce NF-kB through phosphorylation.
1.8 Mitogen Activated Protein Kinases
MAP kinases, currently numbering over a dozen, have provided a focal point for 
remarkably rapid advances in our understanding of the control of cellular events by 
receptors for growth factors and cytokines. Mitogen-activated protein (MAP) Kinases 
are serine / threonine specific protein kinases that respond to extracellular stimuli 
(mitogens) and regulate various cellular activities, such as gene expression, mitosis, 
differentiation, and cell survival / apoptosis (Akira et al, 2001). Extra-cellular stimuli
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lead to activation of a MAP kinase via a signaling cascade composed of MAP kinase, 
MAP kinase kinase (MKK), and MAP kinase kinase kinase (MKKK). Negative 
regulation of MAPK activity is effected primarily by MAPK phosphatases (MKPs). 
Four distinct groups of MAPK’s have been characterised in mammals. Extra-cellular 
signal regulated kinases (ERKs) (Valledor et al., 2000). The ERKs also known as 
classical MAP kinases signaling pathway are preferentially activated in response to 
growth factors and regulates cell proliferation and cell differentiation. c-Jun N- 
terminal kinases (JNKs), also known as stress activated protein kinases (SAPKs). p38 
Isoforms, both JNK and p38 signaling pathways are responsive to stress stimuli such 
as cytokines, UV irradiation, heat shock, and osmotic shock and are involved in cell 
differentiation and apoptosis. ERK5 has been the recent MAPK found and is activated 
by growth factors and by stress stimuli and it participates in cell proliferation 
(Valledor et al., 2000). ERK1, ERK2, JNK, and P38 are all involved in TNFa 
biosynthesis. All three families of MAPKs have been shown to be activated in 
macrophages using a variety of stimuli.
TLR4 the signaling receptor for LPS requires the association of TLR 4 with another 
molecule, MD-2, required for LPS recognition (Akashi et al., 2000). This association 
with MD-2 is essential for activation of MAPKs and phosphorylation of the 
transcription factor Elk-1 (Yang et al., 2000). TNFa can also induce activation of 
macrophage through binding to its receptors (TNFR1 and TNFR2). This binding 
initiates the association of TNF receptor associated proteins to the cytoplasmic end of 
TNF receptors leading to the induction of either a death pathway or a survival 
pathway. (See fig 1.1). When cells are stimulated with activating factors, such as LPS,
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macrophages stop proliferating and produce pro-inflammatory cytokines (Valledor et
al., 2000).
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MAPK Cascade
Fig 1.1 MAPK Pathways
ERK1 and ERK2 Cascade:
ERKl and ERK2 are proteins of 43 and 41 kDa that are nearly 85% identical overall, 
with much greater identity in the core regions involved in binding of substrates 
(Boulton et al., 1990, Schieven, 2005). Tyrosine and threonine are phosphorylated to 
activate the kinases. They are activated by serum, growth factors, cytokines, certain 
stresses and ligands for G protein-coupled receptors (GPCRs). ERKl and ERK2 are 
activated by a MEKS, MEK1 and MEK2 (Crews et al., 1992, Kosako et al., 1992). 
Both of these MEKs have been shown to fully activate ERK1/2 in vitro (Robinson et 
al., 1996, Zheng and Guan, 1993). Raf isoforms and Mos (MEKK’s) are the only
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phosphorylators of MEKs in a single cascade. These proteins appear to phosphorylate 
only two MEK family members, MEK1 and MEK2, placing these MEKKs 
exclusively in the ERK1/2 MAP kinase cascade (Dent et al., 1992, Force et al., 1994, 
Kyriakis et al., 1992).
Perhaps the most well defined signaling pathway from the cell membrane to ERK1 
and ERK2 is that used by receptor tyrosine kinases (Hunter, 1995, Pawson and Scott, 
1997). The cascade plays a central role in the induction of processes such as 
proliferation, differentiation, development, and under certain conditions also in cell 
survival, learning, migration and apoptosis. The cascade is first activated by an 
extracellular stimuli binding to receptors present on the cell surface. Stimulation of 
these receptors by the appropriate ligand results in an increase in receptor catalytic 
activity and subsequent autophosphorylation on tyrosine residues. Phosphorylation of 
these receptors results in the formation of multiprotein complexes whose organization 
dictates further downstream signaling events (Akira et al, 2001). The signaling within 
the cell is initiated by activation of small G proteins (e.g. Ras), which transmit the 
signal further by recruiting the MAP3K tier Raf kinases to the plasma membrane, 
where they are activated. This is achieved by the recruitment of adaptor proteins, such 
as She and Grb2, to the receptor through interactions between their SH2 domains and 
phosphotyrosine residues. (Fig 1.2). The guanine nucleotide exchange factor (GEF) 
then becomes engaged with the complex and induces Ras to exchange GDP for GTP. 
GTP-ligand bound Ras is capable of directly interacting with a number of effectors, 
including Raf isoforms, of which the best characterized is Raf-1 (Dent et al., 1992, 
Moodie et al., 1993). Localization of Raf to the plasma membrane also allows protein 
kinases such as Src, PKC, and PAK to further modify RAF to increase its activity 
(Diaz et al., 1997).
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ERK activation has been shown to promote 1L-10 production and regulate ÏL-12 
production. Studies using ERK inhibitors have shown that ERK activation suppresses 
IL-12 production in macrophages (Feng et al., 1999), and dendritic cells (Puig-Kroger 
et al., 2001). ERK activation has been shown to also be essential for IL-10 production 
in dendritic cells, as inhibition of ERK completely abrogated IL-10 production 
(Loscher et al., 2005).
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Fig 1,2 ERK Cascade (Taken from www.biochemj.org)
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c-Jun N-terminal kinases/stress-activated protein kinases 
(JNK/SAPK)
JNK/SAPKs are activated upon phosphorylation of two sites, a tyrosine and threonine, 
like other MAP kinases (Derijard et al., 1994). They are activated by inflammatory 
cytokines such as EL-1, lymphotoxin-p, TNF, and TGF-(3, certain ligands for GPCRs, 
agents that interfere with DNA and protein synthesis, many other stresses, and to 
some extent by serum, growth factors, and transforming agents. (Fig 1.3). JNKs are 
important in controlling programmed cell death or apoptosis. (Derijard et al., 1994). 
JNK proteins are involved in cytokine production, the inflammatory response, stress- 
induced and developmentally programmed apoptosis, actin reorganization, cell 
transformation and metabolism.
JNK has been shown to be involved in IL-1 p production. The inhibition of JNKs 
enhances chemotherapy-induced inhibition of tumor cell growth, suggesting that 
JNKs may provide a molecular target for the treatment of cancer. JNK inhibitors have 
also shown promise in animal models for the treatment of rheumatoid arthritis. A 
selective JNK inhibitor, SP600125, has been found to be mildly anti-inflammatory in 
the rat adjuvant-induced arthritis, but provides increased protection against bone and 
cartilage destruction (Han et al., 2001). Of the JNK isoforms, JNK2 is particularly 
important in arthritis because it is the dominant isoform expressed in synoviocytes. A 
study utilising an inhibitor which blocked all three isoforms of JNK, marked bone 
protection was seen in the rat adjuvant arthritis model together with decreased 
synovial API activation and collagenase-3 gene expression (Hammaker et al., 2003). 
A JNK2 specific inhibitor in collagen induced arthritis using JNK2 knockout mice 
showed mild joint protection and a modest decrease in cartilage and bone damage. An
inhibitor which blocks both JNK1 and JNK2 is needed to significantly reduce damage 
(Hammaker et al., 2003). Two of the MEK family members have been implicated in 
the JNK/SAPK pathways, these are MKK4 and MKK7. Both MKK4 and MKK7 have 
the ability to phosphorylate p38 family members in vitro and when over-expressed, 
although JNK/SAPKs are the preferred substrates.
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Fig. 1.3 JNK/SAPK Pathway (taken from www.the-scientist.com)
p38
p38 MAP kinase has four isoforms (a,p,y,S) and plays an especially important role in 
the production of cytokines such as interleukin (IL)-1, tumour necrosis factor a 
(TNFa) and IL-6. p38a was discovered independently in three contexts. It was found 
as a tyrosine phosphoprotein present in extracts of cells treated with inflammatory 
cytokines as the target of a pyridinyl imidazole drug that blocked production of tumor
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necrosis factor-a (TNFa) and as such was called cytokine-suppressive anti­
inflammatory drug-binding protein or CSBP and as a reactivating kinase for MAP 
kinase-activated protein (MAPKAP) kinase-2 (Han et al., 1994, Lee et al., 1994, 
Rouse et al., 1994).
The p38 MAPKs regulate the expression of many cytokines. p38 is activated in 
immune cells by inflammatory cytokines and has an important role in activation of the 
immune response. Because the p38 MAPKs are key regulators of inflammatory 
cytokine expression, they appear to be involved in human diseases such as asthma and 
autoimmunity. Several MAPK p38 inhibitors have been shown to block the 
production of interleukin-1 (IL-1), tumour-necrosis factor-a (TNF-a) and other pro- 
inflammatory cytokines (Ono and Han, 2000). A variety of agents including 
cytokines, hormones, GPCRs, osmotic and heat shock, and other stresses activate p38 
family members. (Fig 1.4).
Two MEK family members, MEK3 and MEK6, have high activity toward p38 MAP 
kinases (Derijard et al., 1995). MEK3 appears to favour phosphorylation of p38a- and 
MEK6 phosphorylates all p38 members (Enslen et al., 2000). Both will also 
phosphorylate JNK/SAPK isoforms. MKK3 is especially important for TNFa-induced 
p38 activation and for the p38-mediated synthesis of IL-12 and IFN-y key cytokines 
in the pathogenesis of IBD (Wysk et al., 1999). p38a shows the strongest increase in 
kinase activity among the MAPKs within the inflamed intestinal mucosa of IBD 
patients (Waetzig and Schreiber, 2003, Waetzig et al., 2002). Thus, p38 has been 
suggested to play a key role in intestinal inflammation, cytokine production, and T 
cell activation in IBD. Various animal models suggest that p38 inhibitors such as
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SB203580 attenuate disease activity, mortality or reduced at least partially pro- 
inflammatory cytokine concentrations (Hove et al., 2002). The tremendous interest in 
p38 MAPK as a therapeutic target for inflammatory diseases stems from an ever­
growing body of data demonstrating the importance of the p38 pathway in the cellular 
response to inflammatory stimuli and the very broad efficacy of p38 inhibitors in 
preclinical animal models of disease. The relevant target is considered to be p38a, one 
of the four isoforms of the enzyme (MAPK14, MAPK11, MAPK13, MAPK12 or 
p38a, P, 8, y, respectively). P38a is found in leukocytes, epithelial cells, smooth 
muscle cells, whereas p388 is more highly expressed in macrophages and p38y in 
skeletal muscle (Schieven, 2005).
At this time, all inhibitors under investigation are dual p38a/p inhibitors. In the 
collagen-induced arthritis or rat adjuvant arthritis models of RA, p38 inhibitors have 
been shown to reduce the arthritis score, to reduce the expression of cytokines such as 
IL-ip, and TNFa (Badger et al., 2001). p38 inhibitors have also been reported to be 
efficacious in models of pain, IBD and asthma (Badger et al., 2001). The p38 
inhibitor SB203580 was found to induce a suppression of TNF-a and an increase in 
IL-10 and inducing an anti-inflammatory response in the inflamed bowel tissue. This 
inhibitor also down regulated colitis-induced activation of NFicB(Karin and Lin, 
2002).
The regulation of TNFa, a key mediator in the inflammatory process in IBD, is 
interconnected with MAPK. Other pro-inflammatory cytokines, like IL-16, which is 
up-regulated in IBD, also activate JNKs and p38 (Krautwald, 1998). p38or, JNK1/2, 
and ERK1/2 were significantly activated in the inflamed colonic mucosa of IBD
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patients, with p38a- exhibiting the strongest activation in both Crohns Disease and 
Ulcerative colitis (Krautwald, 1998).
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Fig 1.4 P38 MAPK signalling cascade (taken from cell signalling)
1.9 Inflammation and Inflammatory Disease:
Inflammation is the complex biological response of vascular tissues to harmful 
stimuli. In the absence of inflammation wounds would never heal and tissue 
destruction would certainly compromise survival of the organism. However, 
inflammation, which runs unchecked, can also lead to a host of inflammatory
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diseases, such as atherosclerosis and rheumatoid arthritis (RA). For this reason 
inflammation is a tightly controlled process. Inflammation is classified as either acute 
or chronic. (Janeway, 2006). Acute inflammation is the initial response to harmful 
stimuli and involves the increased movement of plasma and leukocytes from the 
blood into the injured tissues.
Neutrophil polymorphs provide the first line of defence of innate immunity to 
pathogens. Chemokines and eicosanoids cause migration of leukocytes to site of 
infection, through chemotactic attraction. Neutrophil production in the bone marrow 
will increase significantly during a period of acute inflammation. Within a few hours, 
the activated neutrophils will phagocytose pathogens and release inflammatory 
mediators. (Janeway, 2006). Among these are the macrophage inflammatory proteins 
(M IP-la and MIP-I (3), which attract circulating macrophages to site of inflammation. 
These macrophages are activated and have increased phagocytosis and increased 
secretion of cytokines. Activated macrophages secrete three cytokines, IL-1, IL-6 and 
TNF-cx. All three cytokines induce coagulation. IL-1 induces increased expression of 
ICAM-1 and VCAM-1. TNF-a and IL-1 also act on macrophage to induce production 
of chemokines. (Hove et al, 2005)
Chronic inflammation leads to a shift in the type of cells present at site of 
inflammation and involves the simultaneous destruction and healing of the tissue from 
the inflammatory process. The accumulation and activation of macrophages is the 
hallmark of chronic inflammation. Two cytokines in particular IFN-y and TNF-a play 
a central role in chronic inflammation. Thl cells and NK cells release IFN-y while 
activated macrophages secrete TNF-a. IFN-y activates macrophages allowing
41
increased expression of MHC II molecules and increased cytokine production leading 
to more effective antigen presentation. (Lewis CE, 1999). In the case of autoimmune 
diseases pharmaceutical intervention is required, for example patients suffering with 
ulcerative colitis, corticosteroids are used for reduction in inflammation. Although 
sometimes effective the side effects can and are severe. They include high blood 
pressure, onset of diabetes, cataracts and stomach ulcers. These therapies also increase 
the risk of infection. In nutritional studies the n-3 PUFA in fish oil have been shown 
to reduce inflammation in patients with ulcerative colitis. For these reasons the 
interest in inflammation and nutritional therapies has become a major area of 
research.
1.10 Polyunsaturated Fatty Acids (PUFA)
Dietary polyunsaturated fatty acids (PUFA) have effects on diverse physiological 
processes impacting normal health and chronic disease, such as the regulation of 
plasma lipid levels, cardiovascular and immune function, insulin action, and neuronal 
development and visual function. Ingestion of PUFA will lead to their distribution to 
virtually every cell in the body with effects on membrane composition and function, 
eicosanoid synthesis, and signaling as well as the regulation of gene expression. Cell 
specific lipid metabolism, as well as the expression of fatty acid-regulated 
transcription factors likely plays an important role in determining how cells respond 
to changes in PUFA composition.
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Structure and Nomenclature:
PUFA belong to the class of simple lipids, as are fatty acids with two or more double 
bonds in cis position. PUFA are named on the number of carbon atoms they contain, 
the number of double bonds and the location of the first double bond counted from the 
methyl end of the fatty acid. The location of the first double bond, counted from the 
methyl end of the fatty acid, is designated by the omega- or n- number. There are two 
main families of PUFA: n-3 and n-6. These PUFA family are not convertible and 
have very different biochemical roles. Linoleic acid (n-6) (LA) and alpha-linolenic 
acid (n-3) (ALA) are two of the main compounds, known as dietary essential fatty 
acids (EFA) these cannot be synthesized by humans and are as such essential in 
dietary intake. Conjugated linoleic acid (CLA) is a mixture of positional and 
geometrical isomers of linoleic acid (C18:2, cis-9, cis-12), an essential fatty acid for 
human and animals, and involves a double bond at positions 8 and 10, 9 and 11, and 
10 and 12 or 11 and 13.
Sources:
The predominant sources of n-3 PUFA are vegetable oils and fish. Vegetables oils are 
the major sources of ALA. In particular, ALA is found in the chloroplast of green 
leafy vegetables, such purslane and spinach, and in seeds of flax, linseed, walnuts, etc. 
Purslane (Portulaca olearacea), is the richest source of ALA of any green leaf 
vegetable (Simopoulos et al, 1989). Moreover, it is one of the few plants known to be 
a source of eicosapentaenoic acid (C20:5 n-3). Other sources include nuts and seeds, 
vegetables and some fruits, which collectively contribute minor quantities of n-3 
PUFA to the diet. Fish is the main source of EPA and of docosahexaenoic acid (C22:6 
n-3). Vegetables are the main sources of n-6 PUFA. The most important n-6 fatty
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acid, LA, is found in large amounts in western diets in com oil, sunflower oil and 
soybean oil (Lauritzen et al., 2001). CLA is found naturally in animal tissues and 
food sources, including ruminant meats, poultry, eggs and dairy products, such as 
cheeses, milk and yogurt that have undergone heat-processing treatments. The 
principal dietary isomer of CLA is cis-9, trans-11 CLA, also known as rumenic acid 
and RA. This isomer is produced in the rumen of ruminant animals by microbial 
metabolism of linoleic and linolenic acids. Cis-9, trans-11 CLA may be absorbed 
directly or undergo further metabolism. Another CLA isomer, also found in ruminant 
tissue, is trans-10, cis-12 CLA. Most of the animal studies to date with CLA have 
used mixtures of CLA isomers that are mostly cis-9, trans-11 CLA and trans-10, cis- 
12 CLA in approximately equal amounts.
A decrease in the amount of n-3 PUFA has lead to an imbalance and increase in the 
ratio of n-6/n-3. Intake of n-3 PUFA is much lower today because of the decrease of 
fish consumption and the industrial production of animal feeds rich in grains 
containing n-6 PUFA, leading to production of meat reach in n-6 and poor in n-3 
PUFA. The same is true for cultured fish and eggs (Simopoulos and Salem, 1989, van 
Vliet and Katan, 1990). Even cultivated vegetables contain fewer n-3 PUFA than do 
plants in the wild (Simopoulos and Salem, 1986).
Effects:
Studies of hunter-gatherer societies indicates that man evolved on a diet that was low 
in saturated fat and the amounts of n-3 and n-6 PUFA was quite equal. In the last 100- 
150 years changes have taken place in the food supply, that lead to increases in 
saturated fat from grain-fed cattle; increases in /ram-fatty acids from the
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hydrogenation of vegetable oils; and enormous increases in n-6 PUFA. The biological 
functions of the n-6 PUFA are diverse. LA is a structural component in the ceramides 
of the water barrier of the skin (Lauritzen et al., 2001). AA is the precursor of 
eicosanoids, the local hormones which participate in physiological and 
pathophysiological conditions (e.g. parturition initiation, platelet aggregation, renal 
electrolyte regulation, blastocyte implantation, and activation of immune cells), n-6 
PUFA also play a role in signal transduction across cell membranes as second 
messengers. The understanding of the essentiality of the n-3 PUFA lags behind but is 
a fast expanding area. The n-3 PUFA can in part substitute for the n-6 PUFA, maybe 
as a sparring effect, in ameliorating some of the EFAs deficiency symptoms (e.g. 
growth retardation), but are now considered also to have their own distinct role. The 
biological functions of dietary n-3 PUFA in the organism are provision of energy and 
carbon atoms. EPA and DHA also serve as a precursor for n-3 eicosanoids, in general 
these have a much lower potency than those derived from the n-6 PUFA and are only 
formed in considerable amounts in tissues at high dietary intakes of EPA and DHA. 
(Lauritzen et al., 2001).
The effects of n-3 PUFA on the synthesis, bioactivity and metabolic clearance of 
eicosanoid products accounts for their anti-inflammatory properties. CLA has been 
shown to modulate the immune system by increasing macrophage killing ability 
(Hayek et al., 1999). CLA is also proapoptotic, and has anticancer properties.
Eicosanoids:
EFA in the plasma membranes serve as substrates for the enzyme cyclooxygenase 
(COX) and lipooxygenase (LOX) and are converted into a number of important, very
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active, short-lived, hormone-like compounds referred to as “eicosanoids”. 
Eicosanoids are signalling molecules, which are derived from n-3 or n-6 fats. These 
signaling molecules exert a complex control over many of the bodys systems 
especially inflammation and immunity. (Lauritzen et al., 2001). They also act as 
messengers in the central nervous system. The n-6 eicosanoids are generally pro- 
inflammatory; n-3's are much less so. The amounts of these fats in a person's diet will 
affect the body's eicosanoid-controlled functions, with effects on cardiovascular 
disease, triglycerides, blood pressure, and arthritis.
Eicosanoids influence numerous metabolic activities including platelet aggregation, 
inflammation, hemorrhage, vasoconstriction and vasodilation, blood pressure and 
immune functions. There are four families of eicosanoids—the prostaglandins, 
prostacyclins, the thromboxanes and the leukotrienes. For each, there are two or three 
separate series, derived either from an n-3 or n-6 essential PUFA. (Luster et al., 
2005a). These series' different activities largely explain the health effects of n-3 and 
n-6 fats. Two families of enzymes catalyze fatty acid oxygenation to produce the 
eicosanoids, cyclooxygenase, or COX, which has at least three isoforms, COX-1, -2, - 
3 -  leading to the prostanoids and, lipoxygenase, in several forms (Luster et al., 
2005b). The eicosanoids from AA (Aracadonic Acid) generally promote 
inflammation. Those from EPA are less inflammatory or even anti-inflammatory. 
The increased dietary intake of PUFA results in the decreased production of 
eicosanoid products. Dietary n-3 and GLA counter the inflammatory effects of AA's 
eicosanoids in three ways along the eicosanoid pathways. Displacement—Dietary n-3 
decreases tissue concentrations of AA. Animal studies show that increased dietary n-3 
results in decreased AA in brain and other tissue. Competitive inhibition—DGLA and
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EPA compete with AA for access to the cyclooxygenase and lipoxygenase enzymes. 
So the presence of DGLA and EPA in tissues lowers the output of AA's eicosanoids. 
Counteraction—Some EPA derived eicosanoids counteract their AA derived 
counterparts.
Anti-inflammatory Effects:
The beneficial effects of n-3 PUFA are derived in part from their effect on the 
immune system. Metabolism of AA and LA derived from the n-6 PUFA, and of EPA 
and ALA derived from the n-3 PUFA, leads to the generation of eicosanoids such as 
prostaglandin’s and leukotrienes. The eicosanoids derived from AA and EPA have 
very similar molecular structures but markedly different biologic effects. For 
example, the EPA-derived eicosanoids are in general much less potent inducers of 
inflammation than the AA-derived eicosanoids. Consequently, a predominance of n-6 
PUFA will result in a pro-inflammatory status with production of prostaglandin’s of 
the 2 series and leukotrienes of the 4 series. (Luster et al., 2005b). As the relative 
amount of n-3 PUFA increases, more prostaglandin’s of the 3 series and leukotrienes 
of the 5 series are produced. These eicosanoids are considered to be less inflammatory 
(Shapiro et al., 1993). A reduction in the amount of the more inflammatory products 
from AA (PGE2 and LTB4), has been implicated as an underlying mechanism for the 
anti-inflammatory effects of fish oil (Meydani and Dinarello, 1993).
The immune response also may be altered by changes in the production of 
immunologic mediators such as cytokines (James et al., 2000). In the case of arthritis 
supplementation with n-3 PUFA can modulate the expression and activity of
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degradative and inflammatory factors that cause cartilage destruction during arthritis. 
Incorporation of n-3 PUFA into articular cartilage chondrocyte membranes results in 
a dose-dependent reduction in expression and activity of proteoglycan degrading 
enzymes (aggrecanases) and expression of inflammation-inducible cytokines (IL-la 
and TNF-oc) and COX-2, but not the constitutively expressed COX-1 (Curtis et al., 
2000).
Studies involving THP-1 monocyte derived macrophages have revealed that DHA 
suppresses the production of inflammatory cytokines TNFa, IL-1 (3 and IL-6, during 
LPS stimulation to a greater degree than EPA (Weldon et al., 2007). IL-8, IL-6 and 
IL-10 expression is lowered by n-3 PUFA and oleate in endothelial cells and 
monocytes, an effect associated with reduced adhesion molecule expression and lower 
adhesion capacity of monocytes (Moore et al., 1993). n-3 PUFA particularly EPA 
have also been shown to decrease IL-12 production, an effect associated with their 
inhibitory effect on lymphocyte proliferation and decreased expression of IL-12R 
(Medzhitov, 2001). Pre-treatment of lymphocytes with DHA or EPA (n-3) can reduce 
the expression of the adhesion molecules L-selectin and LFA-1 (Fiorentino et al., 
1991b). Fish oil rich diets (n-3 PUFA) are associated with higher TGF-(31 expression 
in T cells (Fiorentino et al., 1991a). This growth factor is implicated in immune 
response modulation.
These findings provide evidence that n-3 PUFA supplementation can specifically 
affect regulatory mechanisms involved in chondrocyte gene transcription and thus 
further advocate a beneficial role for dietary fish oil supplementation in alleviation of 
several of the physiological parameters that cause and propagate arthritic disease. In
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Ulcerative Colitis patients LTB4 and PGE2, both products of AA metabolism, are 
increased. In ulcerative colitis LTB4 is an impoxtant mediator of inflammation and 
has the ability to recruit additional neutrophils from the blood stream into the mucosa, 
exacerbating the disease process by further increase LTB4 (Stenson et al., 1992). 
Four months of diet supplementation with fish oil in patients with ulcerative colitis 
resulted in reductions in rectal dialysate LTB4 levels, improvements in histologic 
findings and weight gain.
Another important molecule produced by phagocytes is nitric oxide (NO). The 
production of NO is catalysed in phagocytes by inducible NO-synthase (iNOS), upon 
cell activation. The transcription of iNOS and the production of NO by macrophages 
can be inhibited by PUFA. NO is important in the microbicidal function but upon cell 
hyperstimulation the effects are harmful to the organism resulting in chronic 
inflammation. PUFAs have an inhibitory effect on phagocytosis but can stimulate the 
process when directly added to cell cultures these include AA and DHA. n-6 PUFA 
have been shown to increase IL-1 production whereas n-3 PUFA have shown a 
decrease (Medzhitov, 2001). CLA has been shown to suppress TNFa, IL-1 (3, and IL- 
6 production in IFNy stimulated RAW macrophages. Animals fed diets rich in n-3 and 
n-6 PUFA have decreased expression levels of LFA-1, ICAM-1 and CD2 (Bohn and 
Autenrieth, 1996). Saturated fatty acids induce NFkB activation and COX-2 
expression but unsaturated fatty acids inhibit both saturated fatty acid and LPS 
induced activation of NFkB and COX-2 expression (Fiorentino et al., 1991b). This 
inhibition of LPS induced NFkB is mediated through suppression of TLR2 and TLR4 
signaling pathways (Bohn and Autenrieth, 1996). Suppression of T cell signalling 
through MAPK pathways has also been elucidated. PUFAs are incorporated into lipid
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rafts where they displace LAT (Fiorentino et al., 1991b). This disruption of the 
subdomain impairs PLCy and calcium signalling. This reduction in calcium response 
leads to the interference with the JNK MAPK pathway. The blocking of the pathway 
interferes with IL-2 production and cell surface expression of IL-2R reducing T cell 
proliferation.
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Chapter 2 
Materials and Methods
2.0 Methods and Materials
2.1 Preparation and handling of reagents
Laboratory chemicals and reagents were stored according to manufacturer’s 
instructions. All were of analytical grade and purchased from Sigma-Aldrich Ireland 
Ltd. (Dublin, Ireland) and BDH Chemicals (VWR International Poole UK) unless 
otherwise stated. Reagents in powder form were prepared in distilled water (dH20), 
unless otherwise stated. Solid reagents were weighed using an electronic balance 
Scout Pro (Ohaus Corporation, NY, USA) in disposable plastic weigh-boats. The pH 
of all solutions was measured using a calibration check microprocessor pH meter 
(Hanna Instruments Ltd.) calibrated with buffers at pH 4.0, pH 7.0 and pH 10.0. All 
solutions were stored at room temperature (RT) unless otherwise stated. For transfer 
of liquid volumes Gilson pipettes were used (Gilson S.A., France). Volumes greater 
than 1 ml were measured using disposable plastic Pasteur or graduated pipettes 
(Sarstedt Ltd, Wexford, Ireland). Graduated pipettes were filled using an electronic 
pipette aid (Drummond, PA, USA). Gloves were used while handling all chemicals 
and hazardous chemicals were opened only in a fume-hood (1200 standard, chemical 
systems control Ltd., Ireland).
2.2 Cell culture
All tissue culture was carried out using aseptic techniques in a class II laminar airflow 
unit (LAF) (Thermo Electron Corporation). The unit was switched on at least 15 min 
before use and swabbed with 70 % (v/v) ethanol (EtOH) before and after use. Cells 
were maintained in a 37°C incubator with (5 %) C 0 2 (95 %) humidified air (Thermo 
Electron Corporation OH USA). The LAF and incubator were cleaned thoroughly 
with 70 % (v/v) EtOH and Vircon (Antec International Suffoc UK) on a weekly basis.
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2.2.1 Cell Line
A murine macrophage cell line J774.2 was used exclusively in this study. The J774.2 
cell line was a gift from Professor Kingston Mills (Trinity College Dublin, Ireland). 
The J774.2 cell line was derived from the cell line on the basis of its ability to 
preferentially metastasise to bone (Lelekakis et al., 1999). The cell line was 
maintained as a monolayer in Roswell Park Memorial Institute (R.P.M.I) 1640 
medium (Gibco-BRL, Paisley, UK), supplemented with 10% (v/v) heat-inactivated 
fetal calf serum (FCS) (Gibco-BRL, Paisley, UK), and 2% Penicillin Streptomycin.
2.2.2 Cell line subculture
J774.2 cell monolayers were passaged every three to four days depending on 
confluency. Cells were examined daily using an inverted microscope (Olympus 
CKX31, Olympus Corporation, Tokyo, Japan). When cell cultures reached 70-80% 
confluency they were either used in experiments and / or sub-cultured as follows. 
RPMI 1640 with 10% (v/v) heat-inactivated fetal calf serum (FCS) (Gibco-BRL, 
Paisley, UK), and 2% Penicillin-Streptomycin-Glutamine (complete media) was pre­
warmed to 37°C. The Flasks were tapped gently to allow the loosely adhered cells to 
detach from surface of flask into the media. The cell suspension was then transferred 
to a 50 ml tube using a graduated pipette and centrifuged in a Universal 32R 
centrifuge (Grant Instruments) at 1200 ipm for 5 min. The supernatant was decanted, 
and the cell pellet resuspended in 10 ml of complete medium. Cells were counted 
using a haemocytometer (Hausser Scientific PA USA) and viability assessed by 
trypan blue dye exclusion (section 2.2.6). Cells were sub-cultured at a ratio of 1:7 or 
1:8 depending on confluency by adding 1 ml aliquots of the cell suspension to 19 ml 
complete RPMI 1640, in a vented 75 cm2 TC flasks (Nunc Roskilde Denmark).
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2.2.3 Preparation of frozen cell stocks
Cell stocks were prepared from cultures that were approximately 70% confluent. 
Cryoprotectant was 10 % (v/v) dimethylsulphoxide (DMSO Sigma MO USA) and 90 
% (v/v) FCS. Cells were harvested as described (2.2.2). A flask of cells was sub­
cultured as described in section 2.2.2. The supernatant was removed and the cells 
were resuspended in 1 ml cryoprotectant and transferred to a 2 ml cryovial (nalgene 
cryoware, Nunc International). The cryovial was sealed, labelled with permanent 
marker and placed at -80°C for 24hrs before transferring to a liquid nitrogen tank 
(Forma Scientific Ltd. Ireland). A large number of master stocks were prepared from 
the initial cell stock. Secondary stocks were generated from the master stocks and 
maintained for experimental use. All experiments were carried out with working 
stocks within thirty passages to reduce experimental error caused by changing cell 
populations.
2.2.4 Revival of frozen cell lines
Cryovials were carefully removed from the liquid nitrogen tank and then quickly 
thawed in a water bath at 37°C in order to minimize any damage to cell membranes. 
The exterior of the cryovial was sterilised with 70 % (v/v) EtOH solution. Cells were 
then mixed within a sterile 50 ml tube containing 10 ml of ice-cold complete medium 
by gentle pipetting, and centrifuged at 1200 rpm for 5 min to pellet cells. The 
supernatant was decanted and the cells were resuspended in 10 ml fresh room 
temperature complete medium and centrifuged again at 1200rpm for 5 min. This 
supernatant was decanted and pellet resuspended in lOmls of fresh pre-warmed 
(37°C) complete media. The cells were then sub-cultured as described in section 
2.2.2. Two passages were required before cells could be used in experiments.
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Cell viability was assessed using the trypan blue dye exclusion test, which is based on 
the ability of viable cells to actively exclude dye, owing to an intact cell membrane. 
Dead cells are unable to exclude the dye and appear blue in colour, when viewed 
under a microscope. 100(0,1 of cell suspension was mixed with 400|il of trypan blue 
solution (0.4% (v/v)) in a 1ml eppindorf tube. After ~ 5 min, this solution was 
applied to a Brightline haemocytometer (Sigma MO USA) and the cells were counted 
under high-power magnification (x400). Cells inside the central grid containing 25 
squares were counted Fig. 2.0. By noting the number of dead cells, the percentage 
viability of the culture could be determined.
Cell density and % viability were determined using the following formulae:
Cells/ml = (N / 4) x 10 x 104
Where, N = mean cell number per field counted, 1 = number of fields counted,
10 = dilution factor, and 104 = constant.
% Viability = (number of live cells counted / total number of cells counted) x 100 
Only cell preparations with > 90 % viability were used for experiments.
2.2.5 Cell enumeration and viability assessment
Standard Haem ocytom eter Chamber
Fig. 2.0 Diagrammatic Representation of Haemocytometer used to count cells
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2.3 Protein Analysis
2.3.1 Preparation of cell lysates for western blotting analysis
Preparation of lysates for western blotting from cultured cells was achieved as 
follows; Cells were plated after cell enumeration and viability at 2xl06 cells/well in 6 
well plates and stimulated for the required time with Lipopolysaccharide or 
PAM3CSK4. Supernatants were removed using a pasteur pipette and lOOpl sample 
buffer added. Cells were scraped using a pasteur pipette and transferred to a sterile 
eppindorf and kept on ice. The cell lysates (on ice) were then sonicated for 60 secs at 
40mA with 2.5 pulses/sec. Lysates were finally boiled at 100°C for 5mins. The 
samples were then either run on a SDS-PAGE gel or stored at -20°C for use at a later 
date.
2.3.2 Denaturing polyacrylamide gel electrophoresis (SDS-PAGE)
Proteins were fractionated by SDS denaturing polyacrylamide gel electrophoresis
(SDS PAGE). 10-12 % (w/v) acrylamide gels are suitable for separation of proteins 
of high molecular weight (20 -  100 kDa). The gel apparatus (E5889 Vertical 
Electrophoresis Unit, Sigma Chemical Ltd, USA) was cleaned with isopropanol and 
assembled. 8.3ml bis-acrylamide (30 % (w/v)) (Sigma Ireland), 6.5 ml 1.875 M Tris- 
HC1 pH 8.8, 9.9 ml dH20 , 250pl SDS (10 % (w/v)), 72 pi TEMED (Sigma Ireland), 
250 pi ammonium persulfate (APS) (10 % (w/v)) (Sigma Ireland). The solution was 
mixed well, (TEMED and APS were added to mixture immediately prior to pouring 
the gel), and poured between the assembled vertical plates. Isopropanol was layered 
on top of the gel mix to exclude air and aid polymerization. The gel was allowed to 
set for approximately 30 mins. Once the gel had set the isopropanol was decanted and
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the gel rinsed with dH20  to remove any remaining isopropanol. A 5 % (w/v) stacking 
gel containing 650(0.1 bis-acrylamide (30 % (w/v)), (Sigma Ireland), 1.25 ml 1.5 M 
Tris-HCl pH 6.8, 3ml dH20 , 50 jal SDS (10 % (w/v)), 30 jal TEMED (Sigma Ireland), 
and 50 ¡al APS (Sigma Ireland), (10 % (w/v) was added to the top of the separating 
gel and a 12-well comb was inserted. The gel was allowed to polymerize for 20 min 
after which time the comb was removed carefully and the wells washed briefly with 
dH20  to remove any un-polymerized material. The wells were straightened using the 
needle of a 1 ml insulin syringe. 10(0.1 of samples were added to the wells of the 
polyacrylamide gel and fractionated at 30 mA per gel in 1 x electrode buffer 
(prepared from a 10 x stock: 15 g Tris, 72 g Glycine, 10 ml SDS (10 % (w/v)), made 
up to 100 ml with dH20), until the bromophenol blue dye front approached the 
bottom of the gel. Pre-stained protein molecular weight markers (New England 
Biolabs Ltd.; MA USA) ranging from 7 -  175 kD were added to one well in each gel. 
These proteins were: 7 kD, aprotinin; 16.5 kD, lysozyme; 25 kD, (5-lactoglobulin A;
32.5 kD, triosephosphatase isomerase; 47.5 kD, aldolase; 62 kD, glutamic 
dehydrogenase; 83 kD, MBP paramyosin; 175 kD, MBP-(3-galactosidase.
2.3.3 Protein transfer using iBlot dry blotting system
When the gel was approaching the end of its run, the iBlot dry blotting electrophoresis 
system was set up. Each protein transfer required a complete iBlot run pack, which 
contained a bottom anode stack and top cathode stack, filter paper and a disposable 
sponge, The bottom anode stack package consisted of a copper electrode, 
nitrocellulose (0.2|iM) membrane and a transfer gel layer all contained in a 
transparent plastic tray, which served as the support for the assembled transfer packs. 
The top cathode stack consisted of a copper electrode and a top transfer gel layer. The 
bottom anode stack was removed from its package and kept in its transparent plastic
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tray. The tray was then aligned with the gel barriers on the blotting surface of the 
iBlot. The pre-run gel was placed on the nitrocellulose membrane of the anode stack 
and a pre-soaked filter paper was placed on the pre-run gels. The blotting roller was 
then used to remove any air bubbles between the membrane and the gel. The top 
cathode stack was removed from its packaging and placed on top of the pre-soaked 
filter paper with the copper electrode side facing upwards. Any bubbles were again 
removed using the blotting roller. The disposable sponge was then placed on the inner 
side of the lid of the iBlot, ensuring its brass metal contact is in exact position for 
contact with the electrical contact on the lid as well as the electrode on the assembled 
iBlot Gel transfer stacks. Gels were then stained with coomassie blue and membranes 
stained with poncheau s or immuno-probed.
2.3.4 Coomassie blue staining
Fractionated proteins were visualized by staining with Coomassie Brilliant Blue dye 
(250 mg Coomassie Brilliant Blue, 45 % (v/v) methanol, 10 % (w/v) glacial acetic 
acid) to determine if electrophoresis was successful and whether proteins were intact 
and loaded equally. The gel was immersed in at least 5 volumes of staining solution 
for approximately 1 hr on a rotating platform. The gel was destained (destaining 
solution: 45 % (v/v) methanol, 10 %(v/v) glacial acetic acid) on a slowly rotating 
platform for approximately 3-4 h until all protein bands were clearly visible and 
background staining was fully eliminated. The bands on both the stained gel and the 
membrane were compared to confirm even loading of protein samples.
2.3.5 Ponceau S staining
After protein transfer the nitrocellulose membrane was stained with Ponceau S 
(Sigma Ireland) to view quality of protein transfer. The membrane was stained with 
20 ml of stain for 5 min on a rotating platform. The transferred proteins were
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visualized following several washes with dH?() to enhance clarity. The protein bands 
appear pink with ponceau S stain. A longer wash with dHoO was used to totally 
remove the stain.
2.3.6 Immunological probing
Membranes were blocked in blocking buffer (5 % (w/v) dried milk in TBS (TBS 
137mM Sodium Chloride, 10 mM Tris, pH is 7.4)), for 1 hr at RT unless otherwise 
stated. Membranes were incubated with the primary antibody (Table 2.1), diluted in 
blocking buffer to the manufactures specifications on a rotating platform (Bellco 
Glass model 7744: Bellco Glass Inc., NJ, USA) for 1.5 h. Membranes were washed 
three times for 5 min each in TBST (TBS containing 0.5 - 1.0 % (v/v) Tween 20 
Sigma Ireland) on the rotating platform. The appropriate species-specific horseradish 
peroxidase (HRP) conjugated secondary antibody (diluted in TBS at 1/2000 unless 
otherwise stated), was then added for 1 hr. Membranes were washed four times for 5 
min each in TBST.
2.3.7 Autoradiography and densitometry
HRP-labeled antibody complexes were visualized using Supersignal West Pico 
Chemiluminescent substrate kit (Pierce ILL USA) for 5 min on a rotating platform. 
Excess substrate was decanted; the membrane was sealed in plastic wrap without 
allowing it to dry out and exposed to X-ray film (Kodak Ltd., Herts, UK) immediately 
in a dark room under red light. The film was developed using an AGFA CPI000 film 
processor (Agfa-Gevaert, Morstel, Belgium). Exposure times varied depending on 
the concentration of protein used and the intensity of signals obtained. Membranes 
were stored in square petri dishes containing 10ml TBS at 4°C. The X-ray film was 
photographed and when appropriate the density of bands on the film was calculated
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using the densitometry program on the GeneSnap gel analysis and documentation 
system GeneTools.
2.3.8 Stripping and re-probing membranes
To re-probe membranes antibody complexes were removed by washing membrane in 
20 ml stripping solution (0.2 M glycine, 10 % (w/v) SDS, I % (v/v) Tween 20, dH2Û 
to 100 ml, pH 2.2 using 12 M HC1) for 30 min at 56°C in a, followed by six 5 min 
washes in TBST. The membrane was then blocked and re-probed.
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Table 2.1 Immunoblotting antibodies used: antibody, concentration, detection method, 
and source of antibody
Antibody Concentration Detection Method 
¿¿Concentration
Secondary
Antibody
Source
pP38 1:1000 dilution of 1:2000 dilution of Anti-Rabbit Cell signaling
(Phospho-P38) antibody HRP-labeled 
secondary antibody
pERK 1:1000 dilution of 1:2000 dilution of Anti-Mouse Cell signaling
(Phospho-ERK) antibody HRP-labeled 
secondary antibody
pJNK (Phospho- 1:1000 dilution of 1:2000 dilution of Anti-Rabbit Cell signaling
JNK) antibody HRP-labeled 
secondary antibody
P38 1:1000 dilution of 1:2000 dilution of Anti-Rabbit Cell signaling
(Total) antibody HRP-labeled 
secondary antibody
ERK 1:1000 dilution of 1:2000 dilution of Anti-Rabbit Cell signaling
(Total) antibody HRP-labeled 
secondary antibody
JNK 1:1000 dilution of 1:2000 dilution of Anti-Rabbit Cell signaling
(Total) antibody HRP-labeled 
secondary antibody
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2.4 Enzyme-Linked Immunosorbent Assay (ELISA)
An ELISA is a biochemical technique used to detect the presence of an antibody or 
antigen/protein in a sample. The ELISA method used in these experiments was the 
sandwich ELISA for detection of secreted proteins. Samples were generated by first 
plating cells at a concentration of lx l0 6/well in a 24 well plate for 24hrs and 
stimulating each well for the required time with either LPS or PAM3CSK4. 
Supernatants were then removed to fresh 24 well plates and were either assessed by 
ELISA straight away or frozen for later use at -20°C. A 96 well ELISA plate was 
coated with lOOfOl of a 1:180 dilution of capture antibody in PBS. The plates were 
incubated overnight at RT. Plates then washed 4X in PBS/Tween. 300(il of blocking 
buffer (1% BSA/PBS) was added to each well and left for lhr at RT. Plates were 
washed again 4X in PBS/Tween. Serial dilutions of standards for each ELISA were 
prepared (Table 2.3). To each well 50(0.1 of blocking buffer (1% BSA/PBS) was added 
(unless stated) and 50jol of either standard or sample. Plates were incubated overnight 
at 4°C. Plates were then washed 4X in PBS/Tween. 100(0.1 of a 1:180 dilution of 
detection antibody in blocking buffer was added to each well and left to incubate for 
2hrs at RT. Plates were washed 4X times in PBS/Tween. 100(01 of a 1:200 dilution of 
Streptavidin-HRP in blocking buffer was added to each well and incubated at RT for 
20mins. Plates were washed a final time in four changes of PBS/Tween and 100pl of 
TMB added to each well. Plates were left at RT until color development and reaction 
was stopped with 1M H2 SO4 . Plates were read at 450nm in a Versa Max Microplate 
Reader (Molecular Devices, USA).
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Flow cytometry is a technology that simultaneously measures and then analyzes 
multiple physical characteristics of single particles, usually cells, as they flow in a 
fluid stream through a beam of light. The properties measured include a particle’s 
relative size, relative granularity or internal complexity, and relative fluorescence 
intensity. Layout and design of cytometer as shown in fig 2.1.
Samples were generated by first plating cells at a concentration of lxlO6 cells/ml in a 
24 well plate and stimulating for the required time with either LPS or PAM3CSK4. 
Cells were then scraped using a transfer pipette in the media and transferred to 15ml 
falcon tubes. Equal amounts of FCS were added to the cells and left at RT for 15mins, 
to block non-specific binding. Tubes were spun at 1200rpm for 5mins. Supematents 
were removed carefully and pellets were resuspended in FACs buffer, approx 1ml per 
2xl06 cells. 200|il of each resuspended pellet was added to a 96 well plate and spun 
again for 5mins at 2000rpm. Supernatant was removed from wells and lOOfxl of 
antibody was added to each well as required (see table 2.2). Pellets were fully 
resuspended in antibody solution and incubated at 4°C for 30mins (See table 2.2 for 
antibodies used in experiments). Plates were spun again at 2000rpm for 5mins, 
supernatants removed and pellets resuspended in 200|j.l of FACs buffer. Plates were 
again spun at 2000rpm for 5 mins. This was repeated a further 3 times. Cells were 
finally fixed in 200|il of 4% formaldehyde/PBS and transferred to labelled FACs 
tubes for analysis. Tubes were read on the flow cytometer FACS calibre and data was 
analysed using Cellquest software (Becton Dickinson, Oxford).
2.5 Flow Cytometry
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Fig 2,1 Picture taken from  http://www.ueb.cas.cz
Table 2.2 Antibodies used in experiments
Antibody Label Catalogue
Number
Supplier
TLR 2 FITC 11-9021-82 EBioscience
TLR4-MD2 PE 12-9924-82 EBioscience
Rat IgG2a FITC 11-4321-82 EBioscience
Rat IgG2a PE 12-4321-82 EBioscience
Rat IgG2b FITC 11-4031-82 EBioscience
Rat IgG2b PE 12-4031-83 EBioscience
Table 2.3 Dilutions of antibodies and source of ELISA kits.
Cytokine Capture
Antibody
Dilution
Standard
Dilution
Detect
Antibody
Dilution
Source
IL-10 1:180 1:60 1:180 R&D
IL-12p40 1:180 1:35 1:180 R&D
TNF-a 1:180 1:135 1:180 R&D
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The results of the experiment are expressed as the mean +/- the standard error of the 
mean (SEM). The SEM is the standard deviation of the distribution of sample mean. 
As sample sizes increase, the SEM. decreases. When the SEM is small, it indicates 
that the distribution of sample means has less error estimating the true mean. S.E.M. 
is calculated as the SD of the original sample divided by the square root of the sample 
size. The data in this study did not need to be normalised and so no transformations 
were necessary. Statistical significance was determined by analysis of variance 
(ANOVA), where the number of groups in the experiment was three or more. A 
probability (P) value of <0.05 was considered to represent a significant difference 
between the groups. A Newman-Keuls Post Hoc test for non-parametric statistical 
analysis was necessary after using ANOVA to determine which groups were 
significantly different to each other. Statistical analysis was computed using 
GraphPad Prism software.
2.5 Statistical Analysis
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Chapter 3 
Results
3.1 Introduction
Inflammation is the complex biological response of vascular tissues to harmful 
stimuli. Inflammation, which runs unchecked, can also lead to a host of inflammatory 
diseases, such as atherosclerosis and rheumatoid arthritis (RA). The accumulation and 
activation of macrophages is the hallmark of chronic inflammation. In the case of 
autoimmune diseases pharmaceutical intervention is required, for example in patients 
suffering with ulcerative colitis, corticosteroids are used to reduce inflammation. 
While these treatments are quite effective, the side effects can be severe. Nutritional 
studies have shown the n-3 PUFA, found in fish oil, to reduce inflammation in 
patients with ulcerative colitis. Several studies show specific effects of these PUFA 
on inflammatory cytokine production, which may explain some of their beneficial 
effects. EPA and DHA suppress the production of inflammatory cytokines TNF-a, IL- 
1(3 and IL-6, following LPS stimulation of immune cells (Weldon et al., 2007). 
Another PUFA, CLA, as well as EPA have been shown to decrease IL-12 production 
in dendritic cells. The mechanisms by which these PUFA exert these effects are still 
relatively unclear.
Macrophages play an important role in innate immunity. They constantly test the 
surrounding area for pathogens and engulf them using pseudopods or by the binding 
of PAMPs present on pathogens, to PRRs on the macrophage cell surface. The most 
common of these PRRs are the TLRs, which are highly expressed by macrophages. In 
macrophages, the presence of these TLRs, serve to identify the nature of the pathogen 
and turn on an effector response appropriate for dealing with it. The resultant 
signaling cascade leads to the expression of various cytokine genes. Activation of
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macrophages results in production of pro-inflammatory cytokines, which if 
dysregulated, can play a major role in inflammatory disease. The cytokines and 
factors produced as a result of activation of PPRs can serve to initiate or sustain host 
responses that are anti-inflammatory (eg, interleukin 10 and transforming growth 
factor p) or pro-inflammatory (eg, TNFa and interleukin 12).
TLR4 binds LPS as well as heat shock proteins released at site of infection and 
damage. TLR4 ligation results in the production of inflammatory cytokines such as 
IL-12 and TNFa. Expression levels of TLR4 have been shown to be enhanced in 
patients with IBD, suggesting that an abnormal mechanism may provide an excess of 
inflammatory mediators during the active phases of IBD. Polymorphisms of TLR4 
have also been studied with higher levels observed in ulcerative colitis and Crohns 
disease patients then in normal population (Harris et al, 2006). Furthermore, TLR4 is 
now believed to play a role in atherosclerosis (Li et al, 2007)
Upon recognition TLR4 triggers intracellular signalling pathways including MAPK 
pathways ERK, JNK and p38 resulting in The MAPK pathways are one of the 
intracellular signalling pathways utilised by TLR4. Activation of ERK has been 
shown to promote IL-10 production and regulate IL-12 production (Yi et al, 2002). 
JNK activation is involved in IL-1 p production. Indeed JNK inhibitors have shown to 
be mildly anti-inflammatory in a rat model of arthritis (Han et al, 2001). Finally p38 
has shown to be involved also in production of EL-1 and TNFa. Inhibitor studies have 
revealed that inhibition of p38 can reduce expression of cytokines IL-ip and TNFa, 
and increased production of IL-10 (Foey et al, 1998). Interestingly p38 is increased 
within the inflamed intestinal mucosal of IBD patients (Waetzig GH et al, 2003).
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This study examines the effects of PUFA on LPS induced cytokine production in 
macrophage as well as expression of TLR4. Furthermore, it investigates the role of 
MAPK activation in mediating these effects.
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3.2 Results
3.2.1 The elucidation of the effects of PUFA concentrations on cell 
viability.
The concentrations of PUFA used in this study are well established in the laboratory 
and have been shown to exert effects on immune cell function while maintaining cell 
viability. To establish that the effects of PUFA we see in our studies are not a result of 
cell death, we examined the effect of several concentrations of PUFA on cell viability. 
J774 murine macrophages, were cultured for 7 days in 25|jM, 50^M and 100(iM 
concentrations of fatty acids. Supernatants were removed and cell viability assessed 
using Cell Titre 96 Aqueous One Solution (Promega, WI, USA) as per manufacturer’s 
instructions. The selected concentrations of fatty acids used in all subsequent 
experiments have no cytotoxic effects on J774 macrophage in vitro. These are as 
follows - DMSO (25pM), CLA (SOpM), EPA (25|oM), DHA (25|oM), LA (25pM), SA 
(25hM). (Fig 3.1)
3.2.2 Assessment of cytokine production by macrophages to 
increasing doses of TLR4 ligand.
To determine the correct dose of the TLR4 ligand for this study we cultured J774 
murine macrophages in fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM) for 7 days, plated them at lxlO6 cells/ml, and 
stimulated them for 24hrs with lOng/ml, lOOng/ml and l|xg/ml of the TLR4 ligand, 
LPS. Supernatants were removed after 24hrs and assessed for levels of IL-10 and IL- 
12p40 using specific immunoassay. Activation of TLR4 by addition of LPS resulted
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in production of IL-10 and IL-12p40. Fig 3.2 demonstrates that IL-10 production was 
enhanced in cells treated with by DHA and CLA but not by EPA. Given the use of 
lOOng/ml of LPS in a number of published studies and our observation that shows 
significant activation of TLR4 at this concentration, we used this concentration for the 
rest of the study.
3.2.3 Effect of PUFA on TLR4 expression
As we were examining the effects of PUFA on TLR4 activation, we felt it was 
important to look at the concomitant effects on expression of TLR4. J774 murine 
macrophages were cultured in fatty acids for 7 days (DMSO 25mM, CLA 50mM, 
DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml and 
stimulated with lOOng/ml LPS for 0, 6 and 24hrs. Cells were then stained with a 
fluorescent antibody specific for TLR4 and expression levels were analysed by flow 
cytometry. Stimulation of J774 macrophages with LPS increased expression of 
TLR4 at 6hr and 24hr 6hr treated cells (Fig 3.3(A)). When we examined the effects of 
PUFA on this expression, we observed an increase in TLR4 expression in cells treated 
with all CLA, EPA and DHA. At 24hr post stimulation, the increase in TLR4 
expression persisted for CLA-treated cells, with the other groups showing no change 
at this time point (Fig 3.3(B)).
3.2.4 PUFA modulate cytokine production by macrophages.
We examined the effects of PUFA on the production of cytokines in response to 
stimulation with the TLR4 ligand, LPS. J774 murine macrophages were cultured in 
presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml and stimulated for 24hrs
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with lOOng/ml LPS. Supernatants were removed and assessed for levels of IL-10, IL- 
12p40 and TNFa using specific immunoassay (Fig 3.4). Treatment of cells with CLA 
and DHA resulted in a significant increase in production of IL-10 following TLR4 
ligation (pcO.OOl, p<0.01 respectively). The levels of IL-10 were not significantly 
affected by the remaining fatty acids. CLA and DHA also suppressed IL-12p40 
production (pcO.OOl) with SA also exerting a small but significant effect. All of the 
fatty acids examined significantly inhibited LPS-induced TNFa production (p<0.01, 
p<0.001).
3.2.5 Effects of PUFA on cytokine production by macrophages in the 
presence of MAPK inhibitors
In order to determine the involvement of MAPK in mediating the effects of PUFA on 
LPS-induced cytokine production in macrophages, cells were cultured in presence of 
fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 25mM, LA 25mM, and 
SA 25mM) for 7 days, plated at lxlO6 per ml, then specific MAPK inhibitors (ERK 
U0126, JNK inhibitor 1, p38 SB20210) were added at 5|iM, lhr prior to stimulation 
with lOOng/ml LPS for 24hrs. Supernatants were removed and assessed for levels of 
IL-10, IL-12p40 and TNFa using specific immunoassay. Treatment of cells with 
CLA resulted in increased production of IL-10 in J774 macrophages following LPS 
stimulation (pcO.OOl; Fig 3.5). This increase was maintained in the presence of the 
specific JNK inhibitor (pcO.OOl) the levels were dramatically decreased in the 
presence of the ERK and p38 inhibitors, although the levels still reached statistical 
significance (pcO.OOl, pc0.05). DHA also significantly enhanced TLR4-induced IL- 
10 production by macrophages (pcO.Ol). This increase was maintained in the 
presence of specific inhibitors to JNK (pcO.OOl) and also in the presence of inhibitors
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to ERK and p38, but to a much lesser extent (pcO.OOl, p<0.05). Treatment of cell 
with CLA resulted in a suppression of LPS-induced IL-12p40 (pcO.OOl; Fig 3.6). This 
effect was maintained in the presence of the ERK and JNK inhibitors, however 
inclusion of a specific inhibitor to p38 reversed this suppressive effect. DHA also 
inhibited LPS-induced IL-12p40 production (pcO.OOl). The inclusion of inhibitors to 
ERK, p38 and JNK did not reverse this effect. Similar results were obtained for the 
SA-treated group. All of the fatty acids examined induced a significant decrease in 
TLR4 induced TNFa production (pcO.Ol; Fig 3.7). This effect persisted in the 
presence of inhibitors to ERK and JNK, but were reversed by the p38 inhibitor.
3.2.6 Modulation of MAPK pathway by PUFA.
Given that the presence of some MAPK inhibitors were shown to reverse the effects 
of PUFA on cytokine production in J774 macrophages after LPS stimulation, we 
investigated whether PUFA enhanced or suppressed activation of these MAPK at a 
number of time points following activation of the cells with the TLR4 ligand, LPS. 
Cells were cultured in presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, 
DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM) and plated at lxlO6 per ml. 
Cells were stimulated with lOOng/ml LPS for the following time points; Ohr, 5 min, 
10 min, 15 min, 30 min, 60 min, 120min, 240 min and 360 min. Cells were then 
scraped and collected into sample buffer, sonicated and boiled prior to loading on 
SDS-PAGE gels. Gels were blotted using iBLOT system. All membranes were 
blocked in 5% Marvel / TBST, then incubated with phosphospecific ERK, p38 or 
JNK 5% BSA, followed by HRP-conjugated secondary Antibody 5% Marvel / TBST 
unless otherwise stated. Membranes were then treated with Chemiluminescent
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Substrate (Pierce) and exposed for required time and developed using FUJI processor. 
Blots were then stripped and re-probed for total protein to demonstrate equal loading. 
Representative blots are shown in the figures. We carried out densitometry using 
GeneSnap and GeneTool in order to graph the results using arbitary units. All DMSO 
groups at all time points were assigned a value of 100 and changes in density of the 
bands calculated accordingly.
3.2.6.1 Modulation of ERK pathway by PUFA
Exposure of J774 macrophages to CLA enhanced activation of ERK following TLR4 
ligation. This was evident 5 min, 30 min, 60 min and 120 min after activation with 
LPS (Fig 3.8, 3.8(A)). Treatment of cells with EPA and DHA did increase ERK 
activation (except for one time point). Indeed a marked decrease in ERK 
phosphorylation was observed at most of the time points examined (Fig 3.9, 3.9(A)). 
In both experiments, the SA treated group inhibited ERK activation at many of the 
time points
3.2.6.2 Modulation of p38 pathway by PUFA
Treatment of J774 macrophages with CLA was observed to enhance phosphorylation 
of p38 at a number of time point post LPS stimulation -  this was evident at 5 min, 10 
min, 15 min and 30 min (Fig 3.10, 3.10(A)). EPA and DHA also enhanced p38 
activation with increased levels observed at 5 min, 10 min, 2hr, 4hr and 6hr post LPS 
stimulation (Fig 3.11, 3.11(A)).
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Treatment of J774 murine macrophages with CLA showed a decrease JNK activity at 
Ohr, 5 min, 10 min, 15 min, 30 min and 2 hr post LPS stimulation (Fig 3.12, 3.12(A)). 
EPA had little if any effect on JNK activation, however DHA treated cells displayed 
enhanced phosphorylation of JNK 5 min, 10 min, lhr, 2hr and 6hr post stimulation 
with LPS (Fig 3.13, 3.13(A)).
3.2.6.3 Modulation of JN K  pathway by PUFA
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Figure 3.1 Fatty Acid concentrations do not affect viability of J774 cells in vitro.
J774 cells were cultured in fatty acids for 7 days at either 25mM, 50mM, or lOOmM. 
Supernatants were removed and cell viability assessed using Cell Titre 96 Aqueous 
One Solution (Promega, WI, USA) as per manufacturer’s instructions. Results are 
expressed as mean +/- SEM. As this experiment was a dose response study comparing 
the best concentrations eliciting an effect no further statistical analysis was required.
74
250
nli
1 0 n g /m l  
lO O n g /m l  
1 (J.g/m  1
DM SO EPA DHA LA SA CLA
3000-
I d 2000-
a  
®
1000- n  
J
lO n g /m l
lO O n g /m l
l ( i g / i n l
DM SO EPA DHA LA SA CLA
Fig 3.2 Cytokine production by J774 murine macrophages following TLR4 
activation. J774 murine macrophages were cultured in fatty acids (DMSO 25mM, 
CLA 50mM, DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM) for 7 days, plated 
at lxlO6 per ml then stimulated for 24hrs with lOng/ml, lOOng/ml and 1 (-ig/ml LPS. 
Supernatants were removed and assessed for levels of IL-10 and IL-12p40 using 
specific Immunoassay.
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Fig 3.3(A) PUFA modulate TLR4 expression on macrophages- J774 murine 
macrophages were cultured in fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, 
EPA 25mM, LA 25mM, and SA 25mM) for 7 days, plated at lxlO6 per ml then 
stimulated for 6hrs with lOOng/ml LPS. Cells were then stained with antibody specific 
for TLR4. In DMSO Figure, grey (fill) represents DMSO treated cells (no 
stimulation), black line (no fill) represents DMSO 6hr stimulated cells, grey line (no 
fill) represents DMSO 24hr stimulated cells. In all other cases grey (Fill) represents 
DMSO 6hr LPS treated cells, black line (no fill) represents 6hr fatty acid treated cells.
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Fig 3.3(B) PUFA modulate TLR4 expression on macrophages. J774 murine 
macrophages were cultured in fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, 
EPA 25mM, LA 25mM, and SA 25mM) for 7 days, plated at IxlO6 per ml then 
stimulated for 24hrs with lOOng/ml LPS. Cells were then stained with antibody 
specific for TLR4. In DMSO figure, grey (fill) represents DMSO treated cells (no 
stimulation), black line (no fill) represents DMSO 24hr stimulated cells, grey line (no 
fill) represents DMSO 24hr stimulated cells. In all other cases Grey (Fill) represents 
DMSO 24hr LPS treated cells, black line (no fill) represents 6hr fatty acid treated 
cells.
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Fig 3.4 PUFA modulate cytokine production by macrophages following TLR4 
activation. J774 murine macrophage were cultured in presence of fatty acids (DMSO 
25mM, CLA 50mM, DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM) for 7 
days, plated at lxlO6 per ml and stimulated for 24hrs with lOOng/ml LPS. 
Supernatants were removed and assessed for levels of IL-10, IL-12p40 and TNFa 
using specific immunoassay. Results are expressed as mean +SEM. *p<0.05; 
**p<0.01; ***p<0.001, ANOVA, comparing DMSO and fatty acid treated groups.
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Figure 3.5 The effects of PUFA on IL-10 production by macrophages in the 
presence of specific MAPK inhibitors. J774 murine macrophages were cultured in 
the presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml +/- specific inhibitors 
(ERK U0126, JNK inhibitor 1, p38 SB20210) at 5p.M added lhr prior to stimulation 
with 100ng/ml LPS for 24hrs. Supernatants were removed and assessed for levels of 
IL-10 using specific immunoassay. Results are expressed as mean +SEM. *p<0.05; 
**p<0.01, ***p<0.001, ANOVA, comparing DMSO and fatty acid treated groups in 
the presence and absence of specific inhibitors.
79
Control
LPS
ERK Inhibitor 
P38 Inhibitor
vy//A  JNK Inhibitor
Figure 3.6 The effects of PUFA on IL-12p40 production by macrophages in the
presence of specific MAPK inhibitors. J774 murine macrophages were cultured in 
the presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml +/- specific inhibitors 
(ERK U0126, JNK inhibitor 1, p38 SB20210) at 5pM added lhr prior to stimulation 
with 100ng/ml LPS for 24hrs. Supernatants were removed and assessed for levels of 
IL-12p40 using specific immunoassay. Results are expressed as mean +SEM. 
*p<0.05; **p<0.01; ***p<0.001, ANOVA, comparing DMSO and fatty acid treated 
groups in the presence and absence of specific inhibitors.
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Figure 3.7 The effects of PUFA on TNFa production by macrophages in the 
presence of specific MAPK inhibitors. J774 murine macrophages were cultured in 
the presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml +/- specific inhibitors 
(ERK U0126, JNK inhibitor 1, p38 SB20210) at 5(xM added lhr prior to stimulation 
with 100ng/ml LPS for 24hrs. Supernatants were removed and assessed for levels of 
TNFa using specific immunoassay. Results are expressed as mean +SEM. **p<0.01; 
***p<0.001, ANOVA, comparing DMSO and fatty acid treated groups in the 
presence and absence of specific inhibitors.
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Figure 3.8: CLA modulates activation of ERK in J774 macrophages following 
TLR4 activation. Cells were cultured with either DMSO, c9, tll-C LA  (50uM) or SA 
(25uM) for 7 days and then stimulated with LPS (lOOng/ml) or medium alone. Cells 
were harvested 0-6h following stimulation and total (bottom panel) and 
phosphorylated ERK (top panel) was determined in whole cell lysates by western 
blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (B) 5 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; 
(C) 10 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (D) 15 min time point: 
Lane 1 DMSO; lane 2 CLA; lane 3 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
CLA; lane 3 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (G) 
120 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (H) 4 hr time point: Lane 
1 DMSO; lane 2 CLA; lane 3 SA.
(I) 6hr time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA.
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Fig 3.8(A) CLA modulates activation of ERK in J774 macrophages following 
TLR4 activation. Densitometrie analysis was carried out on immunoblots shown in 
Fig 4.8. pERK is expressed as arbitary units.
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Figure 3.9: EPA and DHA modulate activation of ERK in J774 macrophages 
following TLR4 activation. Cells were cultured with either DMSO, EPA (25uM), 
DHA (25uM) or SA (25uM) for 7 days and then stimulated with LPS (lOOng/ml) or 
medium alone. Cells were harvested 0-6h following stimulation and total (bottom 
panel) and phosphorylated ERK (top panel) was determined in whole cell lysates by 
western blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 
DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (B) 5 min time point: Lane 1 DMSO; 
lane 2 EPA; lane 3 DHA; lane 4 SA; (C) 10 min time point: Lane 1 DMSO; lane 2 
EPA; lane 3 DHA; lane 4 SA; (D) 15 min time point: Lane 1 DMSO; lane 2 EPA; 
lane 3 DHA; lane 4 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 
DHA; lane 4 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; 
lane 4 SA; (G) 120 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 
SA; (H) 4 hr time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (I) 6hr 
time point: Lane 1 DMSO; lane 2 EPA; lane DHA; lane 4 SA.
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Fig 3.9(A) EPA and DHA modulate activation of ERK in J774 macrophages 
following TLR4 activation. Densitometrie analysis was carried out on immunoblots 
shown in Fig 4.9. pERK is expressed as arbitary units.
85
Tjine: 1 2 3
Figure 3.10: CLA modulates activation of p38 in J774 macrophages following 
TLR4 activation. Cells were cultured with either DMSO, c9, tl  1-CLA (50uM) or SA 
(25uM) for 7 days and then stimulated with LPS (lOOng/ml) or medium alone. Cells 
were harvested 0-6h following stimulation and total (bottom panel) and 
phosphorylated p38 (top panel) was determined in whole cell lysates by western 
blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (B) 5 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; 
(C) 10 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (D) 15 min time point: 
Lane 1 DMSO; lane 2 CLA; lane 3 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
CLA; lane 3 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (G) 
120 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (H) 4 hr time point: Lane 
1 DMSO; lane 2 CLA; lane 3 SA.
(I) 6hr time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA.
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Fig 3.10(A) CLA modulates activation of p38 in J774 macrophages following 
TLR4 activation. Densitometrie analysis was carried out on immunoblots shown in 
Fig 4.10. Pp38 is expressed as arbitary units.
87
la n e :  1 2  3 4
Lane: 1 2  3 4 \ Lane: 1 2  3 4
B
Lane: 1 2  3 4
Lane: 1 2  3 4
D
E
• » « f l
Lane: 1 2  3 4
Lane: 1 2  3 4
Lane: 1 2  3 4
m
Lane: 1 2  3 4
'.I
F
G
H
Figure 3.11: EPA and DHA modulate activation of p38 in J774 macrophages 
following TLR4 activation. Cells were cultured with either DMSO, EPA (25uM), 
DHA (25uM) or SA (25uM) for 7 days and then stimulated with LPS (lOOng/ml) or 
medium alone. Cells were harvested 0-6h following stimulation and total (bottom 
panel) and phosphorylated p38 (top panel) was determined in whole cell lysates by 
western blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 
DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (B) 5 min time point: Lane 1 DMSO; 
lane 2 EPA; lane 3 DHA; lane 4 SA; (C) 10 min time point: Lane 1 DMSO; lane 2 
EPA; lane 3 DHA; lane 4 SA; (D) 15 min time point: Lane 1 DMSO; lane 2 EPA; 
lane 3 DHA; lane 4 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 
DHA; lane 4 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; 
lane 4 SA; (G) 120 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 
SA; (H) 4 hr time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (I) 6hr 
time point: Lane 1 DMSO; lane 2 EPA; lane DHA; lane 4 SA.
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Fig 3.11(A) EPA and DHA modulate activation of p38 in J774 macrophages 
following TLR4 activation. Densitometrie analysis was carried out on immunoblots 
shown in Fig 4.11. Pp38 is expressed as arbitary units.
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Figure 3.12: CLA modulates activation of JNK in J774 macrophages following 
TLR4 activation. Cells were cultured with either DMSO, c9, tl 1-CLA (50uM) or SA 
(25uM) for 7 days and then stimulated with LPS (lOOng/ml) or medium alone. Cells 
were harvested 0-2h following stimulation and total (bottom panel) and 
phosphorylated JNK (top panel) was determined in whole cell lysates by western 
blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (B) 5 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; 
(C) 10 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (D) 15 min time point: 
Lane 1 DMSO; lane 2 CLA; lane 3 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
CLA; lane 3 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (G) 
120 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA.
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Fig 3.12(A) CLA modulates activation of JNK in J774 macrophages following 
TLR4 activation. Densitometrie analysis was carried out on immunoblots shown in 
Fig 4.12. pJNK is expressed as arbitary units.
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Figure 3.13: EPA and DHA modulate activation of JNK in J774 macrophages 
following TLR4 activation. Cells were cultured with either DMSO, EPA (25uM), 
DHA (25uM) or SA (25uM) for 7 days and then stimulated with LPS (lOOng/ml) or 
medium alone. Cells were harvested 0-6h following stimulation and total (bottom 
panel) and phosphorylated JNK (top panel) was determined in whole cell lysates by 
western blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 
DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (B) 5 min time point: Lane 1 DMSO; 
lane 2 EPA; lane 3 DHA; lane 4 SA; (C) 10 min time point: Lane 1 DMSO; lane 2 
EPA; lane 3 DHA; lane 4 SA; (D) 15 min time point: Lane 1 DMSO; lane 2 EPA; 
lane 3 DHA; lane 4 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 
DHA; lane 4 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; 
lane 4 SA; (G) 120 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 
SA; (H) 4 hr time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (I) 6hr 
time point: Lane 1 DMSO; lane 2 EPA; lane DHA; lane 4 SA.
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Fig 3.13(A) EPA and DHA modulate activation of JNK in J774 macrophages 
following TLR4 activation. Densitometrie analysis was carried out on immunoblots 
shown in Fig 4.13. pJNK is expressed as arbitary units.
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3.3 Discussion
The main findings of this study are that PUFA can modulate the response of 
macrophages to the TLR4 ligand, LPS. This is evidenced by changes in MAP kinase 
activation, cytokine production, and expression of TLR4. In addition, this study also 
establishes the differential effects of PUFA suggesting that these effects are mediated 
through a number of different pathways.
Treatment of macrophages with CLA results in a significant enhancement of IL-10 
following stimulation with LPS. CLA exerted similar effects in the presence of the 
JNK inhibitor, however CLA’s positive effect on IL-10 was reversed in the presence 
of ERK and P38 inhibitors. Western blotting analysis demonstrated an increase in 
phosphorylation of p38 and ERK but not JNK, with CLA treatment. CLA was also 
shown to up-regulate TLR4 expression in macrophages. Similar results were observed 
with DHA treatment, which enhanced LPS-induced IL-10. This effect was lessened 
considerably in the presence of inhibitors to ERK and p38. Further analysis showed 
that DHA increased p38 activity but had almost no effect on activation of ERK. DHA 
was also shown to induce modest up-regulation of TLR4 expression in macrophage. 
The effects observed with DHA were not seen with EPA. There have been very few 
studies that demonstrate differential actions of these two PUFA. Many studies have 
shown similarities but no definitive differences.
IL-10 is one of the most important anti-inflammatory cytokines within the human 
immune response. It is especially important as it is a potent deactivator of macrophage 
pro-inflammatory cytokine synthesis (Brandtzaeg et al., 1996, Clarke et al., 1998).
9 4
IL-10 also inhibits Thl immune responses by reducing the capacity of macrophages to 
produce IL-12, a potent inducer of Thl responses. IL-10 is a potent anti-inflammatory 
therapy in IBD as it also has a role in the regulatory network of cytokines in 
controlling mucosal tolerance. Indeed, IL-10 deficient mice have been shown to 
spontaneously develop colitis further emphasising its role as an anti-inflammatory 
therapy in IBD (Tamagawa et al., 2007). Few studies have examined the effects of 
PUFA on production of IL-10. We have previously reported that CLA enhances IL-10 
production by dendritic cells (Loscher et al., 2005). Furthermore, EPA has been 
shown to increase IL-10 in the brain, suggesting that it exerts anti-inflammatory and 
neuroprotective effects in the central nervous system (Lynch et al., 2003). More 
recently, Sierra et al, showed that n-3 PUFA reduced innate and specific immune 
responses partially through an increase in IL-10 (Sierra et al., 2006). However, there 
are still a number of contradictory studies that show dietary fish oil to suppress IL-10 
production (Skuladottir et al., 2007). We have reported a significant difference 
between the effects of EPA and DHA on IL-10 production, which may explain some 
of the findings of these studies.
We also report that CLA inhibited LPS-induced IL-12p40 in murine macrophage. 
Inhibitor studies show that this inhibition was dependent on the P38 MAPK kinase 
intracellular signalling cascade but not on the ERK or JNK cascades. Furthermore, 
western blotting analysis showed a sustained increase in phosphorylation of p38 in 
CLA-treated cells following LPS stimulation, with only small amounts of ERK 
phosphorylation, and no change in JNK. CLA was also shown to up-regulate TLR4 
expression in macrophage. DHA treatment also inhibited LPS-induced IL-12p40 
production, an effect that was maintained even in the presence of inhibitors to ERK,
95
p38 and JNK. Although cells treated with DHA did demonstrate increased p38 
activity. Again there were clear differences between the effects of EPA and DHA, 
with EPA showing no significant effect on IL-12p40 production. All of the PUFA 
examined in this study resulted in suppression of TNFa production following 
stimulation with LPS. This effect was unaffected by the addition of inhibitors to ERK 
and JNK but was reversed by inhibition of p38.
IL-12 and TNFa are important pro-inflammatory cytokine that have been found to be 
involved in autoimmune diseases like IBD. Indeed dysregulation of their synthesis is 
key in the inflammatory pathogenesis of these diseases. Therefore tight control of IL- 
12 and TNFa are crucial to avoid inflammatory and autoimmune disease. (H Wang et 
al). TNFa is mainly produced by macrophages although lymphoid cells, mast cells, 
endothelial cells, fibroblasts and neuronal tissue can also produce it. TNFa plays a 
central role in chronic inflammation. High levels of pro-inflammatory cytokines, 
including TNFa, in the intestinal mucosa are pivotal in the development of relapses 
and for sustaining chronic inflammation (Mascheretti et al., 2004). Our findings that 
PUFA suppress pro-inflammatory cytokine production by immune cells are in 
agreement with numerous studies. We have previously reported that CLA suppressed 
IL-12 production by DC (Loscher et al., 2005), an effect also reported for EPA and 
DHA (Wang et al., 2007).
It is well established that MAPK activation is involved in the regulation of cytokines. 
Activation of ERK has been shown to promote IL-10 production and regulate IL-12 
production. p38 has been shown to be involved in production of IL-1 and TNFa. 
While the effects of PUFA on suppression of pro-inflammatory cytokine production
96
have been widely reported, the involvement of MAPK in mediating these effects, are 
less well defined. Further complexity is added by reports that demonstrate PUFA to 
have different effects on MAPK activity in different cell populations. We have 
reported that CLA activated ERK in DC with subsequent effects on cytokine 
production. Furthermore, DHA has been shown to inhibit apoptosis via activation of 
ERK (German et al., 2006). However, both DHA and EPA have been shown to 
suppress ERK activity in T cells (Denys et al., 2001). These conflicting effects can 
also be seen when examining the literature on PUFA and p38 activation. DHA and 
EPA have been shown to inhibit mineralisation of vascular cells via activation of p38 
(Abedin et al., 2006), however, recently these PUFA were reported to modulate 
activation of DC through inhibition of p38 activity (Wang et al., 2007) and were also 
shown to decrease activation of p38 as well as ERK and JNK in microglia (Moon et 
al, 2007). It is clear from these reports that the effects of PUFA on activation of 
MAPK, varies greatly between cell types.
Our study clearly shows that CLA enhances IL-10 and suppresses IL-12p40 
production by macrophages following TLR4 activation and these effects are mediated 
by p38 and ERK. We also show that DHA significantly increases IL-10 production in 
LPS-stimulated macrophages via the same pathway but can suppress IL-12p40 
production independently of MAPK activation. These effects were not seen with EPA 
and therefore demonstrate differentia] effects of these PUFA. Given that TLR4 has 
been shown to be involved in a number of inflammatory diseases, these data may 
explain the beneficial effects of PUFA in these diseases.
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Chapter 4 
Results
4.1: Introduction
As discussed in the previous chapter, inflammation, which runs unchecked, leads to 
inflammatory diseases such as atherosclerosis, rheumatoid arthritis and IBD. Dietary 
intervention with PUFAs have been shown to have beneficial effects in these diseases. 
TLR2 has now been shown to play a role in the development and progression of these 
diseases; however the effects of PUFA on TLR2 have not yet been explored.
TLR2, in association with TLR1 or TLR6, recognizes various bacterial components, 
including peptidoglycan, lipopeptide and lipoprotein of Gram-positive bacteria and 
mycoplasma lipopeptide. There are a variety of cytokines produced as a result of TLR 
ligation, including IL-10, IL-2, IL-6 and IL-12. TLR2-mediated cellular activation 
may play a role in protection from pathogens that contain specific TLR2 ligands. 
Higher expression of TLR2 was also found in both Crohns disease and ulcerative 
colitis suggesting that an abnormal mechanism may provide an excess of 
inflammatory mediators during the active phases of IBD (Canto et al., 2006). 
Alternatively, the increase in TLR2 expression could serve to enhance levels of the 
anti-inflammatory cytokine, IL-10, in an effort to restore homoeostasis to the local 
environment in this disease.
Activation of TLR2 leads to a signaling cascade involving the MAP kinases -  ERK, 
p38 and JNK. These have been shown to be involved in the regulation of cytokines 
downstream of TLR activation. For example, ERK activation has been shown to 
promote IL-10 production and regulate IL-12 production. Studies using ERK 
inhibitors have shown that ERK activation suppresses IL-12 production in
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macrophages (Feng et al., 1999) and dendritic cells (Puig-Kroger et al., 2001). ERK 
activation has been shown to also be essential for IL-10 production in dendritic cells, 
as inhibition of ERK completely abrogated IL-10 production (Loscher et al., 2005).
This study examines the effects of PUFA on TLR activation in macrophages by 
assessing their effects on cytokine production and TLR2 expression. Furthermore, it 
investigates the role of MAPK activation in mediating these effects.
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4.2 Results
4.2.1 The effects of PUFA concentrations on cell viability.
The concentrations of PUFA used in this study are well established in the laboratory 
and have been shown to exert effects on immune cell function while maintaining cell 
viability. To establish that the effects of PUFA we see in our studies are not a result of 
cell death, we examined the effect of several concentrations of PUFA on cell viability. 
J774 murine macrophages were cultured for 7 days in 25pM, 50(.iM and 100 pM 
concentrations of fatty acids. Supernatants were removed and cell viability assessed 
using Cell Titre 96 Aqueous One Solution (Promega, WI, USA) as per manufacturer’s 
instructions. The selected concentrations of fatty acids used in all subsequent 
experiments have no cytotoxic effects on J774 macrophage in vitro. These are as 
follows - DMSO (25pM), CLA (50hM), EPA (25pM), DHA (25 hM), LA (25jiM), SA 
(25 (xM). (Fig 4.1)
4.2.2 Assessment of cytokine production by macrophages to 
increasing doses of TLR2 ligand.
To determine the correct dose of the TLR2 ligand for this study we cultured J774 
murine macrophages in fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM) for 7 days, plated them at lxlO6 cells/ml, and 
stimulated them for 24hrs with lOng/ml, lOOng/ml and lpg/ml of the TLR2 ligand, 
PAM3CSK4. Supernatants were removed after 24hrs and assessed for levels of IL-10 
and IL-12p40 using specific immunoassay. Activation of TLR2 by addition of 
PAM3CSK4 resulted in production of IL-10 and IL-12p40. Fig 4.2 demonstrates that
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IL-10 and IL-12p40 production was enhanced in cells treated with by EPA, CLA but 
not by DHA. Given the use of ] (ig/rnl of PAM3CSK4 in a number of published 
studies and our observation that shows significant activation of TLR2 at this 
concentration, we used this concentration for the rest of the study.
4.2.3 PUFA modulate TLR2 expression on macrophages.
When determining the effects of compounds on TLR2 activation, it is important to 
look at the concomitant effects on expression of TLR2. J774 murine macrophages 
were cultured in fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, 
EPA 25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml and stimulated with 
lpg/ml PAM3CSK4 for 0, 6 and 24hrs. Cells were then stained with a fluorescent 
antibody specific for TLR2 and expression levels were analysed by flow cytometry. 
Stimulation of J774 macrophages with PAM3CSK4 increased expression of TLR2 at 
6hr and 24hr 6hr treated cells (Fig 4.3(A)). When we examined the effects of PUFA 
on this expression, we observed an increase in TLR2 expression in cells treated with 
all fatty acids. At 24hr post stimulation, the increase in TLR2 expression persisted for 
CLA-treated cells, with EPA and LA- treated cells showing no change and indeed 
DHA was shown to decrease TLR2 expression at this time point (Fig 4.3(B)).
4.2.4 PUFA modulate cytokine production by macrophages.
We examined the effects of PUFA on the production of cytokines in response to 
stimulation with the TLR2 ligand, PAM3CSK4. J774 murine macrophages were 
cultured in presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 
25mM, EPA 25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml and 
stimulated for 24hrs with l(ig/ml PAM3CSK4. Supernatants removed and assessed
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for levels of IL-10, IL-12p40 and TNFa using specific immunoassay. (Fig 4.4) 
Treatment of cells with CLA and EPA resulted in a significant increase in production 
of IL-10 following TLR ligation (pcO.OOl). The levels of IL-10 were unaffected by 
the remaining fatty acids. All of the fatty acids examined induced an increase in IL- 
12p40 production in macrophages activated with PAM3CSK4 (PcO.OOl). The levels 
of TNFa measured were well below the detection limit of the ELISA kit and so no 
statistical analysis was performed on this data.
4.2.5 Effects of PUFA on cytokine production by macrophages in the 
presence of MAPK inhibitors
In order to determine the involvement of MAPK in mediating the effects of PUFA on 
cytokine production in macrophages, cells were cultured in presence of fatty acids 
(DMSO 25mM, CLA 50mM, DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM) 
for 7 days, plated at lxlO6 per ml, then specific MAPK inhibitors (ERK U0126, JNK 
inhibitor 1, p38 SB20210) were added at 5|iM, lhr prior to stimulation with l(j,g/ml 
PAM3CSK4 for 24hrs. Supernatants were removed and assessed for levels of IL-10, 
IL-12p40 and TNFa using specific immunoassay. Treatment of cells with CLA 
resulted in increased production of IL-10 in J774 macrophages following TLR 
ligation (pcO.OOl; Fig 4.5). This increase was not maintained in the presence of 
specific inhibitors to ERK, p38 or JNK. EPA also significantly enhanced TLR2- 
induced IL-10 production by macrophages (pcO.OOl). This increase was maintained 
in the presence of specific inhibitors to ERK, p38 and JNK, with significant increases 
still being detected in these groups (pcO.OOl, pcO.OOl, pcO.OOl respectively). All of 
the fatty acids examined induced a significant increase in TLR-2 induced IL-12p40 
production in J774 macrophages (pcO.OOl; Fig 4.6). This increase was maintained in
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all fatty acid groups upon the inclusion of a specific ERK inhibitor (p<0.001) and 
JNK inhibitor (p<0.001) except for the SA group. The effects of these fatty acids on 
IL-12p40 were reversed in the presence of the specific p38 inhibitor. Once again the 
levels of TNFa detected were nominal (Fig 4.7) and so the data was not analysed 
statistically.
4.2.6 Modulation of MAPK pathway by PUFA.
Given that the presence of some MAPK inhibitors were shown to reverse the effects 
of PUFA on cytokine production in J774 macrophages, we investigated whether 
PUFA enhanced or suppressed activation of these MAPK at a number of time points 
following activation of the cells with the TLR2 ligand, PAM3CSK4. Cells were 
cultured in presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 
25mM, EPA 25mM, LA 25mM, and SA 25mM) and plated at lxlO6 per ml. Cells 
were stimulated with lug/ml PAM3CSK4 for the following time points; Ohr, 5 min, 
10 min, 15 min, 30 min, 60 min, 120min, 240 min and 360 min. Cells were then 
scraped and collected into sample buffer, sonicated and boiled prior to loading on 
SDS-PAGE gels. Gels were blotted using iBLOT system. All membranes were 
blocked in 5% Marvel / TBST, then incubated with phosphospecific ERK, p38 or 
JNK 5% BSA, followed by HRP-conjugated secondary Antibody 5% Marvel / TBST 
unless otherwise stated. Membranes were then treated with Chemiluminescent 
Substrate (Pierce) and exposed for required time and developed using FUJI processor. 
Blots were then stripped and re-probed for total protein to demonstrate equal loading. 
Representative blots are shown in the figures. We earned out densitometry using 
GeneSnap and GeneTool in order to graph the results using arbitary units. All DMSO
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groups at all time points were assigned a value of 100 and changes in density of the 
bands calculated accordingly.
4.2.6.1 Modulation of ERK pathway by PUFA
Exposure of J774 macrophages to CLA enhanced activation of ERK following TLR2 
ligation. This was evident 5 min, 10 min, 15 min and 60 min after activation with 
PAM3CSK4 (Fig 4.8, 4.8(A)). Cells treated with EPA and DHA also showed 
increased phosphorylation of ERK at the following time points Ohr, 5 min, 15 min, 30 
min and then again later at 2hr and 4 hr post stimulation with PAM3CSK4 (Fig 4.9, 
4.9(A)). In contrast the saturated fatty acid control, SA, suppressed ERK activation at 
a number of time points.
4.2.6.2 Modulation of p38 pathway by PUFA
Treatment of J774 macrophages with CLA had little effect on p38 activation. There 
were some very small increases observed 2hr and 4 hr post stimulation (Fig 4.10, 
4.10(A)). EPA had the most noted effect with increased activation of p38 at 5 min, 10 
min, 15 min and later at 4hr and 6hr post TLR2 ligation (Fig 4.11, 4.11(A)). DHA 
treatment of macrophages also enhanced p38 activation at 5 min and to a lesser extent 
at 30 min post stimulation. SA had mixed effects with some increases at early time 
points and decreased activation at later time points.
4.2.6.3 Modulation of JNK pathway by PUFA
Treatment of J774 murine macrophages with CLA had no effect on JNK activation at 
any of the time points examined (Fig 4.12, 4.12 (A)). While EPA and DHA enhanced
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JNK activation in resting cells, they inhibited JNK activation 5 min, 10 min, 15 min, 
30 min and later at 6 hrs post stimulation with PAM3CSK4 (Fig 4.13, 4.13(A)).
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Figure 4.1 Fatty Acid concentrations do not affect viability of J774 cells in vitro.
J774 cells were cultured in fatty acids for 7 days at either 25mM, 50mM, or lOOmM. 
Supernatants were removed and cell viability assessed using Cell Titre 96 Aqueous 
One Solution (Promega, WI, USA) as per manufacturers instructions. Results are 
expressed as mean +/- SEM. As this experiment was a dose response study comparing 
the best concentrations eliciting an effect no further statistical analysis was required.
106
750-1
g 500-
'530
ft
o
d  25° '
Lu u ni J=LlDMSO CLA DHA EPA LA 4-SAa
I -  1 1 0 ng/ml
■ ■  1 0 0 ng/ml 
I I ljig/ml
s
■8bft
©
a.<N
450-
400-
350
300J
250
200
150
100-
50-
0 1 Hi T Üf l L o i
1 1 0 ng/ml 
1 1 0 0 ng/ml 
I l(Xg/ml
DMSO CLA DHA EPA LA SA
Fig 4.2 Cytokine production by J774 murine macrophages following TLR2 
activation. J774 murine macrophages were cultured in fatty acids (DMSO 25mM, 
CLA 50mM, DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM) for 7 days, plated 
at lxlO6 per ml then stimulated for 24hrs with 10ng/ml, 100ng/ml and 1 (ig/ml 
PAM3CSK4. Supernatants were removed and assessed for levels of IL-10 and IL- 
12p40 using specific immunoassay.
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Fig 4.3(A) PUFA modulate TLR2 expression on macrophages. J774 murine 
macrophages were cultured in fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, 
EPA 25niM, LA 25mM, and SA 25mM) for 7 days, plated at lxlO6 per ml then 
stimulated for 6hrs with lpg/ml PAM3CSK4. Cells were then stained with antibody 
specific for TLR2. In DMSO figure, grey (fill) represents DMSO treated cells (no 
stimulation), black line (no fill) represents DMSO 6hr stimulated cells, grey line (no 
fill) represents DMSO 24hr stimulated cells. In all other cases grey (Fill) represents 
DMSO 6hr PAM3CSK4 treated cells, black line (no fill) represents 6hr fatty acid 
treated cells.
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Fig 4.3(B) PUFA modulate TLR2 expression on macrophages. J774 murine 
macrophages were cultured in fatty acids (DMSO 25mM, CLA 50mM, DHA 25mM, 
EPA 25mM, LA 25mM, and SA 25mM) for 7 days, plated at lxlO6 per ml then 
stimulated for 24hrs with lj.tg/ml PAM3CSK4. Cells were then stained with antibody 
specific for TLR2. In DMSO figure, grey (fill) represents DMSO treated cells (no 
stimulation), black line (no fill) represents DMSO 6hr stimulated cells, grey line (no 
fill) represents DMSO 24hr stimulated cells. In all other cases grey (Fill) represents 
DMSO 24hr PAM3CSK4 treated cells, black line (no fill) represents 24hr fatty acid 
treated cells.
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Fig 4.4 PUFA modulate cytokine production by macrophages following TLR2 
activation. J774 murine macrophage were cultured in presence of fatty acids (DMSO 
25mM, CLA 50mM, DHA 25mM, EPA 25mM, LA 25mM, and SA 25mM) for 7 
days, plated at lxlO6 per ml and stimulated for 24hrs with l|xg/ml PAM3CSK4. 
Supernatants were removed and assessed for levels of IL-10, IL-12p40 and TNFa 
using specific immunoassay. Results are expressed as mean +SEM. ***p<0.001, 
ANOVA, comparing DMSO and fatty acid treated groups.
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Figure 4.5 The effects of PUFA on IL-10 production by macrophages in the 
presence of specific MAPK inhibitors. J774 murine macrophages were cultured in 
the presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml +/- specific inhibitors 
(ERK U0126, JNK inhibitor 1, p38 SB20210) at 5p.M added lhr prior to stimulation 
with l|ig/ml PAM3CSK4 for 24hrs. Supernatants were removed and assessed for 
levels of IL-10 using specific immunoassay. Results are expressed as mean ±SEM. 
**p<0.01, ***p<0.001, ANOVA, comparing DMSO and fatty acid treated groups in 
the presence and absence of specific inhibitors.
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Figure 4.6 The effects of PUFA on IL-12p40 production by macrophages in the 
presence of specific MAPK inhibitors. J774 murine macrophages were cultured in 
the presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM), plated at lxlO6 per ml +/- specific inhibitors 
(ERK U0126, JNK inhibitor 1, p38 SB20210) at 5pM added lhr prior to stimulation 
with lpg/ml PAM3CSK4 for 24hrs. Supernatants were removed and assessed for 
levels of IL-12p40 using specific immunoassay. Results are expressed as mean 
±SEM. ***p<0.001, ANOVA, comparing DMSO and fatty acid treated groups in the 
presence and absence of specific inhibitors.
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Figure 4.7 The effects of PUFA on TNFa production by macrophages in the 
presence of specific MAPK inhibitors. J774 murine macrophages were cultured in 
the presence of fatty acids for 7 days (DMSO 25mM, CLA 50mM, DHA 25mM, EPA 
25mM, LA 25mM, and SA 25mM)( plated at lxlO6 per ml +/- specific inhibitors 
(ERK U0126, JNK inhibitor 1, p38 SB20210) at 5pM added lhr prior to stimulation 
with lpg/ml PAM3CSK4 for 24hrs. Supernatants were removed and assessed for 
levels of TNFa using specific immunoassay. Results are expressed as mean ±SEM. 
The levels detected were below the recommended detection level of the immunoassay 
and so statistical analysis was not performed on this data.
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Figure 4.8: CLA modulates activation of ERK in J774 macrophages following 
TLR2 activation. Cells were cultured with either DMSO, c9, tll-C L A  (50uM) or SA 
(25uM) for 7 days and then stimulated with PAM3CSK4 (lug/ml) or medium alone. 
Cells were harvested 0-2h following stimulation and total (bottom panel) and 
phosphorylated ERK (top panel) was determined in whole cell lysates by western 
blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (B) 5 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; 
(C) 10 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (D) 15 min time point: 
Lane 1 DMSO; lane 2 CLA; lane 3 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
CLA; lane 3 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (G) 
120 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA.
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Fig 4.8(A) CLA modulates activation of ERK in J774 macrophages following 
TLR2 activation. Densitometrie analysis was carried out on immunoblots shown in 
Fig 3.8. pERK is expressed as arbitary units.
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Figure 4.9: EPA and DHA modulate activation of ERK in J774 macrophages 
following TLR2 activation. Cells were cultured with either DMSO, EPA (25uM), 
DHA (25uM) or SA (25uM) for 7 days and then stimulated with PAM3CSK4 
(lug/ml) or medium alone. Cells were harvested 0-6h following stimulation and total 
(bottom panel) and phosphorylated ERK (top panel) was determined in whole cell 
lysates by western blotting. A representative immunoblot is shown. (A) 0 hr time 
point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (B) 5 min time point: 
Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (C) 10 min time point: Lane 1 
DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (D) 15 min time point: Lane 1 DMSO; 
lane 2 EPA; lane 3 DHA; lane 4 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
EPA; lane 3 DHA; lane 4 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 EPA; lane 
3 DHA; lane 4 SA; (G) 120 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; 
lane 4 SA; (H) 4 hr time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; 
(I) 6hr time point: Lane 1 DMSO; lane 2 EPA; lane DHA; lane 4 SA.
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Fig 4.9 EPA and DHA modulate activation of ERK in J774 macrophages 
following TLR2 activation. Densitometrie analysis was carried out on immunoblots 
shown in Fig 3.9. pERK is expressed as arbitary units.
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Figure 4.10: CLA modulates activation of p38 in J774 macrophages following 
TLR2 activation. Cells were cultured with either DMSO, c9, tl 1-CLA (50uM) or SA 
(25uM) for 7 days and then stimulated with PAM3CSK4 (lug/ml/ml) or medium 
alone. Cells were harvested 0-6h following stimulation and total (bottom panel) and 
phosphorylated p38 (top panel) was determined in whole cell lysates by western 
blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (B) 5 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; 
(C) 10 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (D) 15 min time point: 
Lane 1 DMSO; lane 2 CLA; lane 3 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
CLA; lane 3 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (G) 
120 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (H) 4 hr time point: Lane 
1 DMSO; lane 2 CLA; lane 3 SA. (I) 6hr time point: Lane 1 DMSO; lane 2 CLA; 
lane 3 SA.
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Fig 4.10 (A) CLA modulates activation of p38 in J774 macrophages following 
TLR2 activation. Densitometrie analysis was carried out on immunoblots shown in 
Fig 3.10. p38 is expressed as arbitary units.
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Figure 4.11: EPA and DHA modulate activation of p38 in J774 macrophages 
following TLR2 activation. Cells were cultured with either DMSO, EPA (25uM), 
DHA (25uM) or SA (25uM) for 7 days and then stimulated with PAM3CSK4 
(lug/ml) or medium alone. Cells were harvested 0-6h following stimulation and total 
(bottom panel) and phosphorylated p38 (top panel) was determined in whole cell 
lysates by western blotting. A representative immunoblot is shown. (A) 0 hr time 
point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (B) 5 min time point:
Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (C) 10 min time point: Lane 1 
DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (D) 15 min time point: Lane 1 DMSO; 
lane 2 EPA; lane 3 DHA; lane 4 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
EPA; lane 3 DHA; lane 4 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 EPA; lane 
3 DHA; lane 4 SA; (G) 120 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; 
lane 4 SA; (H) 4 hr time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; 
(I) 6hr time point: Lane 1 DMSO; lane 2 EPA; lane DHA; lane 4 SA.
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Fig 4.11 EPA and DHA modulate activation of p38 in J774 macrophages 
following TLR2 activation. Densitometrie analysis was carried out on immunoblots 
shown in Fig 3.10. P38 is expressed as arbitary units.
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Figure 4.12: CLA modulates activation of JNK in J774 macrophages following 
TLR2 activation. Cells were cultured with either DMSO, c9, tl 1-CLA (50uM) or SA 
(25uM) for 7 days and then stimulated with PAM3CSK4 (lug/ml) or medium alone. 
Cells were harvested 0-2h following stimulation and total (bottom panel) and 
phosphorylated JNK (top panel) was determined in whole cell lysates by western 
blotting. A representative immunoblot is shown. (A) 0 hr time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (B) 30 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 
SA; (C) 60 min time point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (D) 120 min time 
point: Lane 1 DMSO; lane 2 CLA; lane 3 SA; (E) 240 min time point: Lane 1 DMSO; 
lane 2 CLA; lane 3 SA; (F) 360 min time point: Lane 1 DMSO; lane 2 CLA; lane 3
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Fig 4.12(A) CLA modulates activation of JNK in J774 macrophages following
TLR2 activation. Densitometrie analysis was carried out on immunoblots shown in 
Fig 3.10. pJNK is expressed as arbitary units.
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Figure 4.13: EPA and DHA modulate activation of JNK in J774 macrophages 
following TLR2 activation. Cells were cultured with either DMSO, EPA (25uM), 
DHA (25uM) or SA (25uM) for 7 days and then stimulated with PAM3CSK4 
(lug/ml) or medium alone. Cells were harvested 0-6h following stimulation and total 
(bottom panel) and phosphorylated JNK (top panel) was determined in whole cell 
lysates by western blotting. A representative immunoblot is shown. (A) 0 hr time 
point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (B) 5 min time point:
Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (C) 10 min time point: Lane 1 
DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; (D) 15 min time point: Lane 1 DMSO; 
lane 2 EPA; lane 3 DHA; lane 4 SA; (E) 30 min time point: Lane 1 DMSO; lane 2 
EPA; lane 3 DHA; lane 4 SA; (F) 60 min time point: Lane 1 DMSO; lane 2 EPA; lane 
3 DHA; lane 4 SA; (G) 120 min time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; 
lane 4 SA; (H) 4 hr time point: Lane 1 DMSO; lane 2 EPA; lane 3 DHA; lane 4 SA; 
(I) 6hr time point: Lane 1 DMSO; lane 2 EPA; lane DHA; lane 4 SA.
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Fig 4.13(A) EPA and DHA modulate activation of JNK in J774 macrophages 
following TLR2 activation. Densitometrie analysis was carried out on immunoblots 
shown in Fig 3.10. pJNK is expressed as arbitary units.
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4.3 Discussion
The main findings of this study are that PUFA can modulate the response of 
macrophages to activation with the TLR2 ligand, PAM3CSK4. This is evidenced by 
the changes in MAP kinase activation, cytokine production, and even expression of 
TLR2 itself. Furthermore, this study demonstrates differential effects of these PUFA, 
suggesting that they may exert their effects through a number of different pathways.
This study shows that treatment of macrophages with CLA results in a significant 
enhancement of IL-10 production following TLR2 ligation. CLA exerted similar 
effects in the presence of a specific JNK inhibitor, however its positive effect on IL- 
10 was completely abrogated in the presence of inhibitors for ERK and p38. Analysis 
of the activation of these MAPK by western blotting revealed that CLA increased 
ERK activation following stimulation with PAM3CSK4, however there was little if 
any effect on p38 phosphorylation. These results suggest that the enhanced IL-10 
production by CLA following TLR2 ligation, are mediated through activation of 
ERK.
EPA-treated macrophage also exhibited an increase in PAM3CSK4-induced IL-10 
production, an effect that was maintained in the presence of specific inhibitors to all 
three MAPK examined. Even though the effect of EPA on IL-10 production was not 
apparently mediated by MAPK activation, we observed that EPA increased activity of 
ERK and to a lesser extent p38, following TLR2 ligation. DHA did not enhance IL-10 
production following PAM3CSK4 stimulation of macrophages. This is suiprising as it 
significantly enhanced IL-10 production following stimulation with the TLR4 agonist,
126
LPS (previous chapter). Interestingly while EPA enhances IL-10 through TLR2, it 
failed to have this effect following activation of TLR4 with LPS. Many studies 
examining the effects of the n-3 PUFA, EPA and DHA, have failed to show any 
individual effects. They have both been shown to suppress NFkB activation and have 
similar effects on production of cytokines such as IL-ip and TNFcx in many cell types 
(Trebble et al., 2003, Weldon et al., 2007). Our data clearly show distinct effects of 
EPA and DHA, depending on the mode of activation of the cell.
IL-10 is the most potent deactivator of macrophage proinflammatory cytokine 
synthesis. IL-10 production has been shown to be enhanced in DC in the gut upon 
encountering gram positive commensals partially through TLR2 activation (Ferwerda 
et al., 2007). Peptidoglycan triggers IL-10 secretion, thereby suggesting a specific 
function in tolerance to commensal Gram-positive bacteria in Human Langerhans 
cells (Flacher et al., 2006). Induction of IL-10 by zymosan, a TLR2 agonist, has also 
been shown to require activation of ERK MAP kinase in murine DC (Slack, 2007). 
These studies demonstrate the importance of ERK and IL-10 following TLR2 
ligation. Furthermore a role for p38 in TLR2 signaling has also been described. TLR 
agonists, particularly PAM3CSK4, have also shown to stimulate human neutrophil 
migration via the activation of ERK and p38 MAPK (Yoshioka and Asai, 2007). 
Furthermore, Horie et al (2007) show that the p38 MAPK pathway is functionally 
linked to IL-10 gene expression and is a step in the upregulation of IL-10 gene 
expression (Horie et al., 2007). Our data suggest that PUFA can enhance IL-10 
production by increasing activation of p38 and ERK, which are downstream of TLR2 
and have already been shown to be important in the production of IL-10.
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Treatment of macrophages with all of the PUFA resulted in an increase in IL-12p40 
production following stimulation with PAM3CSK4. This effect was maintained in the 
presence of the ERK and JNK inhibitor but was somewhat reversed with the addition 
of an inhibitor to p38. EPA perhaps demonstrates the strongest effect on p38 activity, 
as measured by western blot, while the other PUFA have little or no effect. The 
observed effect on IL-12p40 does not seem to be dependent on MAPK activation and 
appears non-specific as all of the PUFA, regardless whether they are saturated or 
unsaturated, exert the same effect. IL-12p40 is an important pro-inflammatory 
cytokine found to be involved in autoimmune disease such as IBD. It was surprising 
to see an increase in this cytokine, given that PUFA suppressed production of this 
cytokine following TLR4 activation. Furthermore, CLA and EPA exert such a 
dramatic effect on IL-10 that the increase in IL-12p40 may not be very significant 
overall.
Activation of TLR2 in macrophages did not result in significant production of TNFa, 
therefore we were unable to assess the impact of the PUFA on this cytokine. In the 
previous chapter, the PUFA had clear effects on TNFa following LPS stimulation and 
the consequences of this have already been discussed.
Our study clearly shows that PUFA can significantly enhance IL-10 and this is 
predominantly associated with activation of ERK. Given that TLR2 had now been 
implicated in a number of diseases such as atherosclerosis and IBD (Harris et al., 
2006, Mullick et al., 2006), and the evidence that PUFA have beneficial effects in 
these disease (Bassaganya-Riera et al., 2002), it is now important to assess the effects 
of PUFA on TLR2 expression and activation as it may provide an insight into how
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PUFA mediate their positive effect in these diseases. At present, ours is the first study 
to demonstrate that PUFA can modulate cytokine production following TLR2 
ligation. Our findings with regard to IL-10 are particularly important. Enhanced 
production of the anti-inflammatory cytokine, IL-10 by PUFA may explain their 
benefits in diseases where increased expression of TLR2 has been shown. The ability 
of PUFA to enhance IL-10 through this receptor may result in significant production 
of EL-10 into the local environment, which inhibits some of the inflammation at the 
site.
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Chapter 5 
General Discussion
5.1 General Discussion
PUFA are nutritionally essential PUFA, essentiality referring to man’s inability to 
synthesise these PUFA leading to complete dependency on the requirement for 
dietary supply. The dietary intake of PUFA results in their incorporation into every 
cell membrane of the body, where they bind to fatty-acid binding proteins and 
undergo metabolic conversions. There appear to be a number of targets for the anti­
inflammatory effects of PUFA, none of which are mutually exclusive. Their effects on 
changes in cytokine production and mode of activation reported in this study will be 
discussed here.
EPA and DHA have been shown to decrease production of pro-inflammatory and T- 
helper 1 cytokines by monocytes and lymphocytes. Sierra et al., 2007, showed that n- 
3 PUFA down-regulate the inflammatory response by enhancing IL-10. Sierra et al., 
2006, have also previously demonstrated that PUFA reduce innate and specific Thl 
and Th2 immune responses increase immunomodulatory cytokines such as DL-10 and 
regulate gene expression. Fish oil rich diets (n-3 PUFA) are associated with higher 
TGF-pi expression in T cells, a growth factor implicated in immune response 
modulation (Sierra et al, 2007). Studies involving THP-1 monocyte-derived 
macrophages have revealed that DHA suppresses the production of inflammatory 
cytokines TNF-a, IL-1 [3 and IL-6, during LPS stimulation to a greater degree than 
EPA (Weldon et al, 2007). These studies show that PUFA can exert an anti­
inflammatory effect. This response is important in the dampening of inflammatory 
disease through IL-lO’s ability to inhibit IL-12 production. Our data aggress with 
these studies and show that PUFA can suppress pro-inflammatory cytokine
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production. Furthermore we provide evidence that these effects are mediated by 
activation of MAPK. Many studies using EPA and DHA have shown similarities 
between the two PUFA, however publications showing clear differences in the actions 
of EPA and DHA are lacking and the mechanisms of action of PUFA are still 
relatively unclear. This study has shown clear differences in their actions.
So far little data is available on the effects of PUFA on TLR2 activation. We however 
have shown that treatment of macrophage with PUFA resulted in a significant 
enhancement of IL-10 in both TLR2 and TLR4 activation. This data suggests that the 
PUFA enhancement of IL-10 is independent of specific TLR activation and may show 
that the relative potent anti-inflammatory nature of IL-10 is through increased 
production of IL-10 by several TLRs. Enhancement of IL-10 by all PUFA was also 
shown to be critically dependent on ERK MAPK activation and to a lesser extent by 
p38. This involvement of ERK was observed in both TLR2 and TLR4 activation. 
Mechanisms determining how PUFA modulate IL-10 are unclear but our data 
suggests that ERK MAPK is of critical importance in inducing increased expression 
of IL-10 by PUFA. CLA enhanced IL-10 production in both TLR2 and TLR4 
activated cells. EPA enhanced IL-10 in TLR2 activated cells only, but no effect was 
observed with TLR4. DHA enhanced IL-10 production in TLR4 activated cells only, 
no effect was observed with TLR2. IL-10 production in all PUFA of this study was 
found to rely on an ERK dependent mechanism. These data suggest differences in the 
modes of activation of IL-10 by PUFA, in particular EPA and DHA. Many studies 
examining the n-3 PUFA, DHA and EPA have failed to show individual effects. 
Consequently, our data is the first to show that differing effects of EPA and DHA on 
IL-10 production is dependent on mode of activation of cell. Furthermore, it clearly
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shows that the mode of activation of cells is critically important in regulation of 
cytokine production.
Our studies show that all PUFAs examined enhanced IL-12p40 production following 
TLR2 activation, however CLA and DHA had an inhibitory effect, while EPA had no 
effect on IL-12p40 following TLR4 activation. Again our data provides evidence that 
DHA and EPA have clear differences in modulation of cytokine production. The 
inhibition of IL-12p40 in TLR4 activated cells shows an anti-inflammatory mode of 
action by the PUFA, as IL-12p40 is a potent pro-inflammatory cytokine. TLR4 is 
known to be involved in many inflammatory diseases and this suppression of 
inflammatory mediator IL-12p40 and enhancement of IL-10 lends weight to growing 
evidence that PUFA exert anti-inflammatory properties. The enhancement of IL- 
12p40 by TLR2 is unclear as there have been no studies to date on the role of PUFA 
on TLR2. Further investigation is required to determine the significance and 
mechanism of action of this increase.
In nutritional studies the n-3 PUFA in fish oil have been shown to reduce 
inflammation in patients with ulcerative colitis. For these reasons the interest in 
inflammation and nutritional therapies has become a major area of research. TLR2 
and TLR4 have been shown in previous studies to be potent producers of pro- 
inflammatory and anti-inflammatory cytokines. Furthermore, TLR4 is now believed 
to play a role in atherosclerosis (Li and Sun, 2007). Higher expression of TLR2 and 
TLR4 were found in both Crohns disease and ulcerative colitis suggesting that an 
abnormal mechanism may provide an excess of inflammatory mediators during the 
active phases of IBD (Canto et al., 2006). Zhao et al., 2007, have showed that
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activation of TLR4 and TLR2, leucine-rich repeat-containing pattern recognition 
receptors, were differentially modulated by saturated and n-3 PUFA in macrophages 
and dendritic cells (Zhao et al., 2007). Naturally occurring PUFA and their 
metabolites are endogenous PPAR y ligands. Bassaganya-Riera et al., 2004, showed 
dietary CLA induced colonic PPAR y expression providing protection against disease 
in a pig model of bacterial-induced colitis (Bassaganya-Riera et al., 2002). Studies in 
animal models and humans show that CLA suppresses inflammation while enhancing 
antigen-specific responses against viral and bacterial pathogens. The decreased 
production of proinflammatory cytokines such as TNF-a in both human and animal 
models by CLA Song et al., 2003, suggests that the immune status is channelled into 
an anti-inflammatory profile. Evidence from diverse sources has suggested that TLRs 
can affect atherosclerosis in multiple ways (Song et al., 2003). Interestingly, CLA has 
been shown to suppress the development of atherosclerosis in experimental models. 
CLAs were shown to lower the release of vasoactive prostanoids from vascular 
smooth muscle cells (SMCs) which play a central role in atherosclerosis
Together our data suggests that PUFA may exert their beneficial effects in these 
diseases, by modulating cytokine production following ligation of multiple TLRs. 
Indeed the effects of PUFA on other TLRs should be examined.
Clearly there is a role for dietary fat modification in altering the inflammatory status 
of cells. Elucidating the exact molecular mechanisms involved in the beneficial 
effects of dietary PUFA will be important in designing novel nutritional-based 
therapies for the prevention and treatment of these diseases.
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